{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T15:17:00Z","timestamp":1789399020803,"version":"build-2803163510"},"reference-count":326,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,8,18]],"date-time":"2025-08-18T00:00:00Z","timestamp":1755475200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Progress in Lipid Research"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.plipres.2025.101343","type":"journal-article","created":{"date-parts":[[2025,8,19]],"date-time":"2025-08-19T15:06:16Z","timestamp":1755615976000},"page":"101343","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["Apolipoproteins in circulation: At the interface of thrombosis and stroke initiation"],"prefix":"10.1016","volume":"100","author":[{"given":"Tamara","family":"Etuze","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denis","family":"Vivien","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatemeh","family":"Dubois","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10","key":"10.1016\/j.plipres.2025.101343_bb0005","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1016\/S1474-4422(24)00369-7","article-title":"Global, regional, and national burden of stroke and its risk factors, 1990\u20132021: a systematic analysis for the Global Burden of Disease Study 2021","volume":"23","year":"2024","journal-title":"Lancet Neurol"},{"issue":"10244","key":"10.1016\/j.plipres.2025.101343_bb0010","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/S0140-6736(20)31179-X","article-title":"Stroke","volume":"396","author":"Campbell","year":"2020","journal-title":"Lancet"},{"issue":"12","key":"10.1016\/j.plipres.2025.101343_bb0015","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1016\/S1474-4422(18)30323-5","article-title":"The role of plasminogen activators in stroke treatment: fibrinolysis and beyond","volume":"17","author":"Thiebaut","year":"2018","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.plipres.2025.101343_bb0020","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1007\/978-1-4020-8831-5_9","article-title":"Altered lipid metabolism in brain injury and disorders","volume":"49","author":"Adibhatla","year":"2008","journal-title":"Subcell Biochem"},{"issue":"4","key":"10.1016\/j.plipres.2025.101343_bb0025","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1007\/s12975-019-00763-2","article-title":"Stroke induces prolonged changes in lipid metabolism, the liver and body composition in mice","volume":"11","author":"Haley","year":"2020","journal-title":"Transl Stroke Res"},{"key":"10.1016\/j.plipres.2025.101343_bb0030","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2024.1470364","article-title":"Atherogenic circulating lipoproteins in ischemic stroke","volume":"11","author":"Benitez","year":"2024","journal-title":"Front Cardiovasc Med"},{"issue":"1","key":"10.1016\/j.plipres.2025.101343_bb0035","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/s12014-024-09465-w","article-title":"Closing the gaps in patient management of dyslipidemia: stepping into cardiovascular precision diagnostics with apolipoprotein profiling","volume":"21","author":"Reijnders","year":"2024","journal-title":"Clin Proteomics"},{"issue":"3","key":"10.1016\/j.plipres.2025.101343_bb0040","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1097\/MOL.0000000000000682","article-title":"Remnant lipoproteins: are they equal to or more atherogenic than LDL?","volume":"31","author":"Salinas","year":"2020","journal-title":"Curr Opin Lipidol"},{"key":"10.1016\/j.plipres.2025.101343_bb0045","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.cca.2018.12.014","article-title":"Remnant lipoproteins and atherosclerotic cardiovascular disease","volume":"490","author":"Tada","year":"2019","journal-title":"Clin Chim Acta"},{"issue":"5\u20136","key":"10.1016\/j.plipres.2025.101343_bb0050","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1159\/000091537","article-title":"Apolipoproteins as predictors of ischaemic stroke in patients with a previous transient ischaemic attack","volume":"21","author":"Bhatia","year":"2006","journal-title":"Cerebrovasc Dis"},{"issue":"6","key":"10.1016\/j.plipres.2025.101343_bb0055","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1007\/s11011-015-9732-7","article-title":"Apolipoprotein A1, B levels, and their ratio and the risk of a first stroke: a meta-analysis and case-control study","volume":"30","author":"Dong","year":"2015","journal-title":"Metab Brain Dis"},{"issue":"1","key":"10.1016\/j.plipres.2025.101343_bb0060","doi-asserted-by":"crossref","first-page":"21","DOI":"10.4103\/0976-3147.91926","article-title":"Carotid intima-media thickness and apolipoproteins in patients of ischemic stroke in a rural hospital setting in Central India: a cross-sectional study","volume":"3","author":"Jain","year":"2012","journal-title":"J Neurosci Rural Pract"},{"issue":"4","key":"10.1016\/j.plipres.2025.101343_bb0065","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1161\/STROKEAHA.121.034299","article-title":"HDL (high-density lipoprotein) subspecies, prevalent covert brain infarcts, and incident overt ischemic stroke: cardiovascular health study","volume":"53","author":"Koch","year":"2022","journal-title":"Stroke"},{"issue":"10046","key":"10.1016\/j.plipres.2025.101343_bb0070","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1016\/S0140-6736(16)30506-2","article-title":"Global and regional effects of potentially modifiable risk factors associated with acute stroke in 32 countries (INTERSTROKE): a case-control study","volume":"388","author":"O\u2019Donnell","year":"2016","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.plipres.2025.101343_bb0075","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1111\/j.1365-2796.2006.01643.x","article-title":"The apoB\/apoA-I ratio: a strong, new risk factor for cardiovascular disease and a target for lipid-lowering therapy--a review of the evidence","volume":"259","author":"Walldius","year":"2006","journal-title":"J Intern Med"},{"issue":"18","key":"10.1016\/j.plipres.2025.101343_bb0080","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1001\/jama.2009.1619","article-title":"Major lipids, apolipoproteins, and risk of vascular disease","volume":"302","author":"Di Angelantonio","year":"2009","journal-title":"JAMA"},{"issue":"3","key":"10.1016\/j.plipres.2025.101343_bb0085","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1038\/s41569-021-00613-5","article-title":"Apolipoproteins in vascular biology and atherosclerotic disease","volume":"19","author":"Mehta","year":"2022","journal-title":"Nat Rev Cardiol"},{"key":"10.1016\/j.plipres.2025.101343_bb0090","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1016\/j.atherosclerosis.2023.06.691","article-title":"Ischemic stroke patients with carotid atherosclerosis show dysfunctional high-density lipoprotein particles","volume":"379","author":"Puig","year":"2023","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.plipres.2025.101343_bb0095","doi-asserted-by":"crossref","DOI":"10.1161\/STROKEAHA.120.032810","article-title":"Thrombus composition and efficacy of thrombolysis and thrombectomy in acute ischemic stroke","author":"Jolugbo","year":"2021","journal-title":"Stroke"},{"issue":"9","key":"10.1016\/j.plipres.2025.101343_bb0100","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1038\/s41569-022-00676-y","article-title":"Metabolism of triglyceride-rich lipoproteins in health and dyslipidaemia","volume":"19","author":"Bor\u00e9n","year":"2022","journal-title":"Nat Rev Cardiol"},{"issue":"4","key":"10.1016\/j.plipres.2025.101343_bb0105","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1161\/STROKEAHA.117.019653","article-title":"Stroke Genetics Network (SiGN). Role of Blood Lipids in the Development of Ischemic Stroke and its Subtypes: A Mendelian Randomization Study","volume":"49","author":"Hindy","year":"2018","journal-title":"Stroke"},{"issue":"6","key":"10.1016\/j.plipres.2025.101343_bb0110","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1002\/ana.25916","article-title":"Circulating lipoprotein lipids, apolipoproteins and ischemic stroke","volume":"88","author":"Yuan","year":"2020","journal-title":"Ann Neurol"},{"issue":"19","key":"10.1016\/j.plipres.2025.101343_bb0115","doi-asserted-by":"crossref","first-page":"6374","DOI":"10.1073\/pnas.82.19.6374","article-title":"Apolipoprotein multigene family: tandem organization of human apolipoprotein AI, CIII, and AIV genes","volume":"82","author":"Karathanasis","year":"1985","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.plipres.2025.101343_bb0120","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2022.113634","article-title":"Leveraging knowledge of HDLs major protein ApoA1: structure, function, mutations, and potential therapeutics","volume":"154","author":"Bhale","year":"2022","journal-title":"Biomed Pharmacother"},{"issue":"7","key":"10.1016\/j.plipres.2025.101343_bb0125","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1038\/labinvest.2016.56","article-title":"ApoA1 and ApoA1-specific self-antibodies in cardiovascular disease","volume":"96","author":"Chistiakov","year":"2016","journal-title":"Lab Invest"},{"issue":"3","key":"10.1016\/j.plipres.2025.101343_bb0130","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1097\/01.mol.0000226110.66942.e8","article-title":"The unique role of apolipoprotein A-I in HDL remodeling and metabolism","volume":"17","author":"Pownall","year":"2006","journal-title":"Curr Opin Lipidol"},{"issue":"9","key":"10.1016\/j.plipres.2025.101343_bb0135","doi-asserted-by":"crossref","first-page":"1890","DOI":"10.1194\/jlr.M026674","article-title":"Nascent high density lipoproteins formed by ABCA1 resemble lipid rafts and are structurally organized by three apoA-I monomers","volume":"53","author":"Sorci-Thomas","year":"2012","journal-title":"J Lipid Res"},{"issue":"1","key":"10.1016\/j.plipres.2025.101343_bb0140","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1038\/s42003-019-0749-z","article-title":"Structural analysis of lecithin:cholesterol acyltransferase bound to high density lipoprotein particles","volume":"3","author":"Manthei","year":"2020","journal-title":"Commun Biol"},{"issue":"5248","key":"10.1016\/j.plipres.2025.101343_bb0145","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1126\/science.271.5248.518","article-title":"Identification of scavenger receptor SR-BI as a high density lipoprotein receptor","volume":"271","author":"Acton","year":"1996","journal-title":"Science"},{"issue":"4","key":"10.1016\/j.plipres.2025.101343_bb0150","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1097\/MOL.0b013e32833c1ef6","article-title":"Marked HDL deficiency and premature coronary heart disease","volume":"21","author":"Schaefer","year":"2010","journal-title":"Curr Opin Lipidol"},{"issue":"37","key":"10.1016\/j.plipres.2025.101343_bb0155","doi-asserted-by":"crossref","first-page":"10713","DOI":"10.1021\/bi7003203","article-title":"LCAT can rescue the abnormal phenotype produced by the natural ApoA-I mutations (Leu141Arg)Pisa and (Leu159Arg)FIN","volume":"46","author":"Koukos","year":"2007","journal-title":"Biochemistry"},{"issue":"11","key":"10.1016\/j.plipres.2025.101343_bb0160","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1515\/BC.2008.156","article-title":"Relevance of the amino acid conversions L144R (Zaragoza) and L159P (Zavalla) in the apolipoprotein A-I binding site for haptoglobin","volume":"389","author":"Cigliano","year":"2008","journal-title":"Biol Chem"},{"key":"10.1016\/j.plipres.2025.101343_bb0165","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.cca.2012.10.017","article-title":"Oxidized ApoC1 on MALDI-TOF and glycated-ApoA1 band on gradient gel as potential diagnostic tools for atherosclerotic vascular disease","volume":"420","author":"Chang","year":"2013","journal-title":"Clin Chim Acta"},{"issue":"1","key":"10.1016\/j.plipres.2025.101343_bb0170","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1002\/jms.1274","article-title":"On the search for glycated lipoprotein ApoA-I in the plasma of diabetic and nephropathic patients","volume":"43","author":"Lapolla","year":"2008","journal-title":"J Mass Spectrom"},{"issue":"34","key":"10.1016\/j.plipres.2025.101343_bb0175","doi-asserted-by":"crossref","first-page":"12224","DOI":"10.1073\/pnas.0802025105","article-title":"Methionine oxidation impairs reverse cholesterol transport by apolipoprotein A-I","volume":"105","author":"Shao","year":"2008","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"10","key":"10.1016\/j.plipres.2025.101343_bb0180","doi-asserted-by":"crossref","first-page":"2002","DOI":"10.1194\/jlr.M059865","article-title":"HDL-apolipoprotein A-I exchange is independently associated with cholesterol efflux capacity","volume":"56","author":"Borja","year":"2015","journal-title":"J Lipid Res"},{"issue":"3","key":"10.1016\/j.plipres.2025.101343_bb0185","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/s11883-021-00906-7","article-title":"APOA1: a protein with multiple therapeutic functions","volume":"23","author":"Cochran","year":"2021","journal-title":"Curr Atheroscler Rep"},{"issue":"6","key":"10.1016\/j.plipres.2025.101343_bb0190","doi-asserted-by":"crossref","DOI":"10.3390\/diagnostics11060984","article-title":"Association between serum concentrations of apolipoprotein A-I (ApoA-I) and Alzheimer\u2019s disease: systematic review and meta-analysis","volume":"11","author":"Zuin","year":"2021","journal-title":"Diagnostics"},{"key":"10.1016\/j.plipres.2025.101343_bb0195","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.vph.2015.10.009","article-title":"Lipoproteins as modulators of atherothrombosis: from endothelial function to primary and secondary coagulation","volume":"82","author":"Ouweneel","year":"2016","journal-title":"Vascul Pharmacol"},{"issue":"5","key":"10.1016\/j.plipres.2025.101343_bb0200","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1182\/blood-2014-09-599530","article-title":"High-density lipoprotein modulates thrombosis by preventing von Willebrand factor self-association and subsequent platelet adhesion","volume":"127","author":"Chung","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.plipres.2025.101343_bb0205","first-page":"20","article-title":"Baseline blood pressure, low- and high-density lipoproteins, and triglycerides and the risk of vascular events in the stroke prevention by aggressive reduction in cholesterol levels (SPARCL) trial","volume":"515","author":"Amarenco","year":"2009","journal-title":"Atherosclerosis"},{"issue":"9","key":"10.1016\/j.plipres.2025.101343_bb0210","doi-asserted-by":"crossref","first-page":"598","DOI":"10.14740\/jocmr4284","article-title":"Association between serum apolipoprotein A1 Levels, ischemic stroke subtypes and plaque properties of the carotid artery","volume":"12","author":"Ohtani","year":"2020","journal-title":"J Clin Med Res"},{"key":"10.1016\/j.plipres.2025.101343_bb0215","doi-asserted-by":"crossref","first-page":"2729","DOI":"10.1001\/jama.285.21.2729","article-title":"High-density lipoprotein cholesterol and ischemic stroke in the elderly: the northern Manhattan stroke study","volume":"285","author":"Sacco","year":"2001","journal-title":"JAMA"},{"key":"10.1016\/j.plipres.2025.101343_bb0220","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1161\/01.STR.0000060869.34009.38","article-title":"High-density lipoprotein cholesterol and risk of stroke in Japanese men and women: the Oyabe study","volume":"34","author":"Soyama","year":"2003","journal-title":"Stroke"},{"key":"10.1016\/j.plipres.2025.101343_bb0225","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.atherosclerosis.2016.08.035","article-title":"Dysfunctional HDL in acute stroke","volume":"253","author":"Ortiz-Munoz","year":"2016","journal-title":"Atherosclerosis"},{"issue":"12","key":"10.1016\/j.plipres.2025.101343_bb0230","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1003853","article-title":"Long-term risk of a major cardiovascular event by apoB, ApoA-I, and the apoB\/ApoA-I ratio-experience from the Swedish AMORIS cohort: a cohort study","volume":"18","author":"Walldius","year":"2021","journal-title":"PLoS Med"},{"key":"10.1016\/j.plipres.2025.101343_bb0235","article-title":"The current status of research on high-density lipoproteins (HDL): a paradigm shift from HDL quantity to HDL quality and HDL functionality","author":"Cho","year":"2022","journal-title":"Int J Mol Sci"},{"issue":"23","key":"10.1016\/j.plipres.2025.101343_bb0240","doi-asserted-by":"crossref","first-page":"4633","DOI":"10.1021\/bi300555d","article-title":"Role of apolipoprotein A-II in the structure and remodeling of human high-density lipoprotein (HDL): protein conformational ensemble on HDL","volume":"51","author":"Gao","year":"2012","journal-title":"Biochemistry"},{"issue":"7","key":"10.1016\/j.plipres.2025.101343_bb0245","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.3390\/biomedicines10071578","article-title":"Apolipoprotein A-II, a player in multiple processes and diseases","volume":"10","author":"Florea","year":"2022","journal-title":"Biomedicines"},{"issue":"7","key":"10.1016\/j.plipres.2025.101343_bb0250","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1194\/jlr.M075382","article-title":"Apolipoprotein A-II alters the proteome of human lipoproteins and enhances cholesterol efflux from ABCA1","volume":"58","author":"Melchior","year":"2017","journal-title":"J Lipid Res"},{"issue":"1","key":"10.1016\/j.plipres.2025.101343_bib1596","doi-asserted-by":"crossref","DOI":"10.1186\/s12944-017-0619-y","article-title":"ApoA-I\/A-II-HDL positively associates with apoB-lipoproteins as a potential atherogenic indicator","volume":"16","author":"Kido","year":"2017","journal-title":"Lipids Health Dis"},{"issue":"1","key":"10.1016\/j.plipres.2025.101343_bb0255","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/S0022-2275(20)39763-7","article-title":"Recruitment of cell phospholipids and cholesterol by apolipoproteins A-II and A-I: formation of nascent apolipoprotein-specific HDL that differ in size, phospholipid composition, and reactivity with LCAT","volume":"36","author":"Forte","year":"1995","journal-title":"J Lipid Res"},{"issue":"3","key":"10.1016\/j.plipres.2025.101343_bb0260","doi-asserted-by":"crossref","DOI":"10.1016\/j.beem.2022.101689","article-title":"The pleiotropic effects of high-density lipoproteins and apolipoprotein A-I","volume":"37","author":"Thomas","year":"2023","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"issue":"18","key":"10.1016\/j.plipres.2025.101343_bb0265","doi-asserted-by":"crossref","first-page":"2029","DOI":"10.1161\/CIRCULATIONAHA.107.704031","article-title":"Apolipoprotein A-II is inversely associated with risk of future coronary artery disease","volume":"116","author":"Birjmohun","year":"2007","journal-title":"Circulation"},{"key":"10.1016\/j.plipres.2025.101343_bb0270","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.atherosclerosis.2020.11.028","article-title":"Human apolipoprotein A-II reduces atherosclerosis in knock-in rabbits","volume":"316","author":"Koike","year":"2021","journal-title":"Atherosclerosis"},{"issue":"2","key":"10.1016\/j.plipres.2025.101343_bb0275","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1161\/ATVBAHA.112.300445","article-title":"Human apolipoprotein A-II protects against diet-induced atherosclerosis in transgenic rabbits","volume":"33","author":"Wang","year":"2013","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"7","key":"10.1016\/j.plipres.2025.101343_bb0280","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1161\/01.ATV.0000022850.59845.E0","article-title":"Value of HDL cholesterol, apolipoprotein A-I, lipoprotein A-I, and lipoprotein A-I\/A-II in prediction of coronary heart disease: the PRIME Study. Prospective Epidemiological Study of Myocardial Infarction","volume":"22","author":"Luc","year":"2002","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"6","key":"10.1016\/j.plipres.2025.101343_bb0285","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1161\/STROKEAHA.115.009663","article-title":"Ratio of apolipoprotein A-II\/B improves risk prediction of postoperative survival after carotid endarterectomy","volume":"46","author":"Duschek","year":"2015","journal-title":"Stroke"},{"key":"10.1016\/j.plipres.2025.101343_bb0290","doi-asserted-by":"crossref","DOI":"10.1253\/circj.CJ-24-0242","article-title":"Serum apolipoprotein-A2 levels are a strong predictor of future cardiovascular events in patients undergoing percutaneous coronary intervention","author":"Akiyama","year":"2024","journal-title":"Circ J"},{"issue":"2 Pt 1","key":"10.1016\/j.plipres.2025.101343_bb0295","first-page":"G277","article-title":"Apolipoprotein A-IV synthesis in proximal jejunum is stimulated by ileal lipid infusion","volume":"270","author":"Kalogeris","year":"1996","journal-title":"Am J Physiol"},{"issue":"8","key":"10.1016\/j.plipres.2025.101343_bb0300","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1194\/jlr.R052753","article-title":"Apolipoprotein A-IV: a protein intimately involved in metabolism","volume":"56","author":"Wang","year":"2015","journal-title":"J Lipid Res"},{"issue":"7","key":"10.1016\/j.plipres.2025.101343_bb0305","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1016\/j.bbalip.2014.03.013","article-title":"Physiological regulation of lipoprotein lipase","volume":"1841","author":"Kersten","year":"2014","journal-title":"Biochim Biophys Acta"},{"issue":"8","key":"10.1016\/j.plipres.2025.101343_bb0310","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1194\/jlr.M300060-JLR200","article-title":"Plasma distribution of apoA-IV in patients with coronary artery disease and healthy controls","volume":"44","author":"Ezeh","year":"2003","journal-title":"J Lipid Res"},{"issue":"4","key":"10.1016\/j.plipres.2025.101343_bb0315","doi-asserted-by":"crossref","first-page":"319","DOI":"10.3390\/cells8040319","article-title":"Apolipoprotein A-IV: a multifunctional protein involved in protection against atherosclerosis and diabetes","volume":"8","author":"Qu","year":"2019","journal-title":"Cells"},{"issue":"4","key":"10.1016\/j.plipres.2025.101343_bb0320","doi-asserted-by":"crossref","first-page":"2258","DOI":"10.1016\/S0021-9258(18)89547-3","article-title":"Activation of lecithin: cholesterol acyltransferase by human apolipoprotein A-IV","volume":"260","author":"Steinmetz","year":"1985","journal-title":"J Biol Chem"},{"issue":"10","key":"10.1016\/j.plipres.2025.101343_bb0325","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1161\/01.ATV.15.10.1755","article-title":"Lipoproteins containing apolipoprotein A-IV but not apolipoprotein A-I take up and esterify cell-derived cholesterol in plasma","volume":"15","author":"von Eckardstein","year":"1995","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"4","key":"10.1016\/j.plipres.2025.101343_bb0330","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1161\/CIRCRESAHA.122.321690","article-title":"Apolipoprotein proteomics for residual lipid-related risk in coronary heart disease","volume":"132","author":"Clarke","year":"2023","journal-title":"Circ Res"},{"key":"10.1016\/j.plipres.2025.101343_bb0335","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.atherosclerosis.2018.11.006","article-title":"Plasma levels of apolipoproteins C-III, A-IV, and E are independently associated with stable atherosclerotic cardiovascular disease","volume":"281","author":"Dittrich","year":"2019","journal-title":"Atherosclerosis"},{"issue":"5277","key":"10.1016\/j.plipres.2025.101343_bb0340","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1126\/science.273.5277.966","article-title":"Protection against atherogenesis in mice mediated by human apolipoprotein A-IV","volume":"273","author":"Duverger","year":"1996","journal-title":"Science"},{"key":"10.1016\/j.plipres.2025.101343_bb0345","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.atherosclerosis.2016.04.019","article-title":"Plaque stabilizing effects of apolipoprotein A-IV","volume":"251","author":"Geronimo","year":"2016","journal-title":"Atherosclerosis"},{"issue":"3","key":"10.1016\/j.plipres.2025.101343_bb0350","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1016\/S0735-1097(00)00775-0","article-title":"Low apolipoprotein A-IV plasma concentrations in men with coronary artery disease","volume":"36","author":"Kronenberg","year":"2000","journal-title":"J Am Coll Cardiol"},{"issue":"4","key":"10.1016\/j.plipres.2025.101343_bb0355","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1161\/01.ATV.0000119353.03690.22","article-title":"Human apolipoprotein A-IV reduces secretion of proinflammatory cytokines and atherosclerotic effects of a chronic infection mimicked by lipopolysaccharide","volume":"24","author":"Recalde","year":"2004","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"6","key":"10.1016\/j.plipres.2025.101343_bb0360","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1161\/01.ATV.21.6.1023","article-title":"Antioxidative and antiatherosclerotic effects of human apolipoprotein A-IV in apolipoprotein E-deficient mice","volume":"21","author":"Ostos","year":"2001","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"5","key":"10.1016\/j.plipres.2025.101343_bb0365","first-page":"H1836","article-title":"Apolipoprotein AIV: a potent endogenous inhibitor of lipid oxidation","volume":"274","author":"Qin","year":"1998","journal-title":"Am J Physiol"},{"issue":"1","key":"10.1016\/j.plipres.2025.101343_bb0370","doi-asserted-by":"crossref","first-page":"C95","DOI":"10.1152\/ajpcell.00388.2005","article-title":"Apolipoprotein A-IV attenuates oxidant-induced apoptosis in mitotic competent, undifferentiated cells by modulating intracellular glutathione redox balance","volume":"290","author":"Spaulding","year":"2006","journal-title":"Am J Physiol Cell Physiol"},{"issue":"2","key":"10.1016\/j.plipres.2025.101343_bb0375","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1007\/s00005-006-0010-6","article-title":"P-selectin mediates adhesion of leukocytes, platelets, and cancer cells in inflammation, thrombosis, and cancer growth and metastasis","volume":"54","author":"Chen","year":"2006","journal-title":"Arch Immunol Ther Exp (Warsz)"},{"issue":"2","key":"10.1016\/j.plipres.2025.101343_bb0380","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1172\/JCI200421233","article-title":"Apolipoprotein A-IV inhibits experimental colitis","volume":"114","author":"Vowinkel","year":"2004","journal-title":"J Clin Invest"},{"issue":"9","key":"10.1016\/j.plipres.2025.101343_bb0385","article-title":"Inhibition of vascular inflammation by apolipoprotein A-IV","author":"Shearston","year":"2022","journal-title":"Front Cardiovasc Med"},{"issue":"1","key":"10.1016\/j.plipres.2025.101343_bb0390","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-018-05806-0","article-title":"Apolipoprotein A-IV binds \u03b1IIb\u03b23 integrin and inhibits thrombosis","volume":"9","author":"Xu","year":"2018","journal-title":"Nat Commun"},{"issue":"5540","key":"10.1016\/j.plipres.2025.101343_bb0395","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1126\/science.1064852","article-title":"An apolipoprotein influencing triglycerides in humans and mice revealed by comparative sequencing","volume":"294","author":"Pennacchio","year":"2001","journal-title":"Science"},{"issue":"48","key":"10.1016\/j.plipres.2025.101343_bb0400","doi-asserted-by":"crossref","first-page":"44512","DOI":"10.1074\/jbc.M106888200","article-title":"Apolipoprotein A-V: a novel apolipoprotein associated with an early phase of liver regeneration","volume":"276","author":"van der Vliet","year":"2001","journal-title":"J Biol Chem"},{"issue":"27","key":"10.1016\/j.plipres.2025.101343_bb0405","doi-asserted-by":"crossref","first-page":"25383","DOI":"10.1074\/jbc.M501589200","article-title":"Apolipoprotein A-V-heparin interactions: implications for plasma lipoprotein metabolism","volume":"280","author":"Lookene","year":"2005","journal-title":"J Biol Chem"},{"issue":"9","key":"10.1016\/j.plipres.2025.101343_bb0410","article-title":"Apolipoprotein A5, a unique modulator of fasting and postprandial triglycerides","volume":"1867","author":"May-Zhang","year":"2022","journal-title":"Biochim Biophys Acta Mol Cell Biol Lipids"},{"issue":"1","key":"10.1016\/j.plipres.2025.101343_bb0415","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.atherosclerosis.2011.07.019","article-title":"Apolipoprotein A-V; a potent triglyceride reducer","volume":"219","author":"Nilsson","year":"2011","journal-title":"Atherosclerosis"},{"issue":"6","key":"10.1016\/j.plipres.2025.101343_bb0420","doi-asserted-by":"crossref","first-page":"2742","DOI":"10.1172\/JCI67398","article-title":"Apolipoproteins E and AV mediate lipoprotein clearance by hepatic proteoglycans","volume":"123","author":"Gonzales","year":"2013","journal-title":"J Clin Invest"},{"issue":"5","key":"10.1016\/j.plipres.2025.101343_bb0425","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1016\/S0006-291X(02)00808-2","article-title":"Adenoviral overexpression of apolipoprotein A-V reduces serum levels of triglycerides and cholesterol in mice","volume":"295","author":"van der Vliet","year":"2002","journal-title":"Biochem Biophys Res Commun"},{"issue":"12","key":"10.1016\/j.plipres.2025.101343_bb0430","doi-asserted-by":"crossref","first-page":"2573","DOI":"10.1161\/01.ATV.0000186189.26141.12","article-title":"Apolipoprotein A-V deficiency results in marked hypertriglyceridemia attributable to decreased lipolysis of triglyceride-rich lipoproteins and removal of their remnants","volume":"25","author":"Grosskopf","year":"2005","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"1","key":"10.1016\/j.plipres.2025.101343_bb0435","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.atherosclerosis.2015.03.008","article-title":"APOA-V variants predispose hyperlipidemic patients to atherogenic dyslipidemia and subclinical atherosclerosis","volume":"240","author":"Guardiola","year":"2015","journal-title":"Atherosclerosis"},{"issue":"2","key":"10.1016\/j.plipres.2025.101343_bb0440","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1194\/jlr.R009720","article-title":"Genetic determinants of plasma triglycerides","volume":"52","author":"Johansen","year":"2011","journal-title":"J Lipid Res"},{"issue":"12","key":"10.1016\/j.plipres.2025.101343_bb0445","article-title":"A promoter variant of the APOA-V gene increases atherogenic LDL levels and arterial stiffness in hypertriglyceridemic patients","volume":"12","author":"Kim","year":"2017","journal-title":"PloS One"},{"issue":"2","key":"10.1016\/j.plipres.2025.101343_bb0450","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/j.bbrc.2004.05.003","article-title":"Mechanism of triglyceride lowering in mice expressing human apolipoprotein A5","volume":"319","author":"Fruchart-Najib","year":"2004","journal-title":"Biochem Biophys Res Commun"},{"issue":"1","key":"10.1016\/j.plipres.2025.101343_bb0455","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1080\/07853890500407488","article-title":"Is apolipoprotein A5 a novel regulator of triglyceride-rich lipoproteins?","volume":"38","author":"Jakel","year":"2006","journal-title":"Ann Med"},{"issue":"5","key":"10.1016\/j.plipres.2025.101343_bb0460","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1161\/CIRCRESAHA.108.179861","article-title":"Atheroprotective effect of human apolipoprotein A5 in a mouse model of mixed dyslipidemia","volume":"103","author":"Mansouri","year":"2008","journal-title":"Circ Res"},{"issue":"1","key":"10.1016\/j.plipres.2025.101343_bb0465","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.atherosclerosis.2012.04.011","article-title":"Apolipoprotein A-V modulates multiple atherogenic mechanisms in a mouse model of disturbed clearance of triglyceride-rich lipoproteins","volume":"224","author":"Grosskopf","year":"2012","journal-title":"Atherosclerosis"},{"issue":"3","key":"10.1016\/j.plipres.2025.101343_bb0470","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1161\/ATVBAHA.112.301078","article-title":"Gene transfer of apolipoprotein A-V improves the hypertriglyceridemic phenotype of ApoA-V (\u2212\/\u2212) mice","volume":"33","author":"Sharma","year":"2013","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"12","key":"10.1016\/j.plipres.2025.101343_bb0475","doi-asserted-by":"crossref","first-page":"2504","DOI":"10.1161\/ATVBAHA.110.210815","article-title":"Intravenous injection of apolipoprotein A-V reconstituted high-density lipoprotein decreases hypertriglyceridemia in apoav\u2212\/\u2212 mice and requires glycosylphosphatidylinositol-anchored high-density lipoprotein-binding protein 1","volume":"30","author":"Shu","year":"2010","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"35","key":"10.1016\/j.plipres.2025.101343_bb0480","doi-asserted-by":"crossref","first-page":"16535","DOI":"10.1016\/S0021-9258(18)66599-8","article-title":"Cloning and expression of human apolipoprotein D cDNA","volume":"261","author":"Drayna","year":"1986","journal-title":"J Biol Chem"},{"issue":"1\u20132","key":"10.1016\/j.plipres.2025.101343_bb0485","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/S0167-4838(00)00162-X","article-title":"Apolipoprotein D","volume":"1482","author":"Rassart","year":"2000","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.plipres.2025.101343_bb0490","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.atherosclerosis.2021.12.011","article-title":"Elevated levels of apolipoprotein D predict poor outcome in patients with suspected or established coronary artery disease","volume":"341","author":"Annema","year":"2022","journal-title":"Atherosclerosis"},{"issue":"6","key":"10.1016\/j.plipres.2025.101343_bb0495","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1194\/jlr.M001206","article-title":"A role of apolipoprotein D in triglyceride metabolism","volume":"51","author":"Perdomo","year":"2010","journal-title":"J Lipid Res"},{"issue":"21","key":"10.1016\/j.plipres.2025.101343_bb0500","doi-asserted-by":"crossref","first-page":"15631","DOI":"10.3390\/ijms242115631","article-title":"Apolipoprotein D as a potential biomarker in neuropsychiatric disorders","volume":"24","author":"Del Valle","year":"2023","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.plipres.2025.101343_bb0505","doi-asserted-by":"crossref","DOI":"10.1016\/j.gene.2020.144874","article-title":"Apolipoprotein D","volume":"756","author":"Rassart","year":"2020","journal-title":"Gene"},{"key":"10.1016\/j.plipres.2025.101343_bb0510","doi-asserted-by":"crossref","DOI":"10.1155\/2022\/8418820","article-title":"The role of oxidative stress in acute ischemic stroke-related thrombosis","volume":"2022","author":"Li","year":"2022","journal-title":"Oxid Med Cell Longev"},{"issue":"3","key":"10.1016\/j.plipres.2025.101343_bb0515","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0034057","article-title":"Molecular dynamics analysis of apolipoprotein-D-lipid hydroperoxide interactions: mechanism for selective oxidation of Met-93","volume":"7","author":"Oakley","year":"2012","journal-title":"PloS One"},{"key":"10.1016\/j.plipres.2025.101343_bb0520","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.jare.2018.03.005","article-title":"Synopsis of arachidonic acid metabolism: a review","volume":"11","author":"Hanna","year":"2018","journal-title":"J Adv Res"},{"issue":"3","key":"10.1016\/j.plipres.2025.101343_bb0525","doi-asserted-by":"crossref","first-page":"986","DOI":"10.3390\/nu13030986","article-title":"Docosahexaenoic and arachidonic acids as neuroprotective nutrients throughout the life cycle","volume":"13","author":"Sambra","year":"2021","journal-title":"Nutrients"},{"issue":"3","key":"10.1016\/j.plipres.2025.101343_bb0530","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0300072","article-title":"Retinoic acid attenuates ischemic injury-induced activation of glial cells and inflammatory factors in a rat stroke model","volume":"19","author":"Kang","year":"2024","journal-title":"PloS One"},{"issue":"6","key":"10.1016\/j.plipres.2025.101343_bb0535","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1093\/protein\/10.6.621","article-title":"Probing the structure of the ligand binding cavity of lipocalins by fluorescence spectroscopy","volume":"10","author":"Patel","year":"1997","journal-title":"Protein Eng"},{"issue":"23","key":"10.1016\/j.plipres.2025.101343_bb0540","doi-asserted-by":"crossref","first-page":"19122","DOI":"10.1021\/acsomega.1c07016","article-title":"Pregnenolone attenuates the ischemia-induced neurological deficit in the transient middle cerebral artery occlusion model of rats","volume":"7","author":"Andrabi","year":"2022","journal-title":"ACS Omega"},{"issue":"4","key":"10.1016\/j.plipres.2025.101343_bb0545","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1007\/s10571-018-0627-0","article-title":"Steroids in stroke with special reference to progesterone","volume":"39","author":"Guennoun","year":"2019","journal-title":"Cell Mol Neurobiol"},{"issue":"5","key":"10.1016\/j.plipres.2025.101343_bb0550","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1007\/s12975-016-0477-3","article-title":"Critical role of the sphingolipid pathway in stroke: a review of current utility and potential therapeutic targets","volume":"7","author":"Sun","year":"2016","journal-title":"Transl Stroke Res"},{"issue":"1","key":"10.1016\/j.plipres.2025.101343_bb0555","doi-asserted-by":"crossref","DOI":"10.1042\/BSR20201423","article-title":"Small angle X-ray scattering analysis of ligand-bound forms of tetrameric apolipoprotein-D","volume":"41","author":"Kielkopf","year":"2021","journal-title":"Biosci Rep"},{"issue":"2","key":"10.1016\/j.plipres.2025.101343_bb0560","article-title":"Cerebral apolipoprotein-D is hypoglycosylated compared to peripheral tissues and is variably expressed in mouse and human brain regions","volume":"11","author":"Li","year":"2016","journal-title":"PloS One"},{"issue":"4","key":"10.1016\/j.plipres.2025.101343_bb0565","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1097\/MOL.0000000000000688","article-title":"Apolipoprotein F: a natural inhibitor of cholesteryl ester transfer protein and a key regulator of lipoprotein metabolism","volume":"31","author":"Liu","year":"2020","journal-title":"Curr Opin Lipidol"},{"issue":"11","key":"10.1016\/j.plipres.2025.101343_bb0570","doi-asserted-by":"crossref","first-page":"1868","DOI":"10.1194\/jlr.RA119000171","article-title":"ApoF knockdown increases cholesteryl ester transfer to LDL and impairs cholesterol clearance in fat-fed hamsters","volume":"60","author":"Morton","year":"2019","journal-title":"J Lipid Res"},{"issue":"3","key":"10.1016\/j.plipres.2025.101343_bb0575","doi-asserted-by":"crossref","first-page":"1814","DOI":"10.1074\/jbc.274.3.1814","article-title":"Molecular cloning and expression of lipid transfer inhibitor protein reveals its identity with apolipoprotein F","volume":"274","author":"Wang","year":"1999","journal-title":"J Biol Chem"},{"issue":"3","key":"10.1016\/j.plipres.2025.101343_bb0580","doi-asserted-by":"crossref","first-page":"347","DOI":"10.3390\/genes15030347","article-title":"Unveiling the impact of ApoF deficiency on liver and lipid metabolism: insights from transcriptome-wide m6A methylome analysis in mice","volume":"15","author":"Shen","year":"2024","journal-title":"Genes (Basel)"},{"issue":"1","key":"10.1016\/j.plipres.2025.101343_bb0585","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1161\/ATVBAHA.108.177105","article-title":"Overexpression of apolipoprotein F reduces HDL cholesterol levels in vivo","volume":"29","author":"Lagor","year":"2009","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"4","key":"10.1016\/j.plipres.2025.101343_bb0590","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1002\/hep.32631","article-title":"Apolipoprotein F is reduced in humans with steatosis and controls plasma triglyceride-rich lipoprotein metabolism","volume":"77","author":"Deprince","year":"2023","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.plipres.2025.101343_bb0595","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1194\/jlr.M700258-JLR200","article-title":"Lipid transfer inhibitor protein (apolipoprotein F) concentration in normolipidemic and hyperlipidemic subjects","volume":"49","author":"Morton","year":"2008","journal-title":"J Lipid Res"},{"issue":"12","key":"10.1016\/j.plipres.2025.101343_bb0600","doi-asserted-by":"crossref","first-page":"3524","DOI":"10.1194\/jlr.P008268","article-title":"Common genetic variation in multiple metabolic pathways influences susceptibility to low HDL-cholesterol and coronary heart disease","volume":"51","author":"Peloso","year":"2010","journal-title":"J Lipid Res"},{"issue":"13","key":"10.1016\/j.plipres.2025.101343_bb0605","article-title":"Blood-based protein biomarkers for the diagnosis of acute stroke: a discovery-based SWATH-MS proteomic approach","author":"Misra","year":"2022","journal-title":"Front Neurol"},{"issue":"Pt 2","key":"10.1016\/j.plipres.2025.101343_bb0610","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1042\/bj3440375","article-title":"Functional and structural properties of lipid-associated apolipoprotein J (clusterin)","volume":"344","author":"Calero","year":"1999","journal-title":"Biochem J"},{"issue":"5\u20136","key":"10.1016\/j.plipres.2025.101343_bb0615","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/S0197-0186(01)00049-3","article-title":"Purification and characterization of astrocyte-secreted apolipoprotein E and J-containing lipoproteins from wild-type and human apoE transgenic mice","volume":"39","author":"DeMattos","year":"2001","journal-title":"Neurochem Int"},{"issue":"12","key":"10.1016\/j.plipres.2025.101343_bb0620","doi-asserted-by":"crossref","first-page":"2528","DOI":"10.1161\/ATVBAHA.110.212894","article-title":"Low clusterin levels in high-density lipoprotein associate with insulin resistance, obesity, and dyslipoproteinemia","volume":"30","author":"Hoofnagle","year":"2010","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"8","key":"10.1016\/j.plipres.2025.101343_bb0625","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1161\/CIRCULATIONAHA.112.108753","article-title":"Altered activation of endothelial anti- and proapoptotic pathways by high-density lipoprotein from patients with coronary artery disease: role of high-density lipoprotein-proteome remodeling","volume":"127","author":"Riwanto","year":"2013","journal-title":"Circulation"},{"issue":"13","key":"10.1016\/j.plipres.2025.101343_bb0630","doi-asserted-by":"crossref","first-page":"164","DOI":"10.3389\/fnins.2019.00164","article-title":"Clusterin in Alzheimer\u2019s disease: mechanisms, genetics, and lessons from other pathologies","author":"Foster","year":"2019","journal-title":"Front Neurosci"},{"issue":"5","key":"10.1016\/j.plipres.2025.101343_bb0635","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/S1357-2725(01)00155-8","article-title":"Clusterin","volume":"34","author":"Jones","year":"2002","journal-title":"Int J Biochem Cell Biol"},{"issue":"18","key":"10.1016\/j.plipres.2025.101343_bb0640","doi-asserted-by":"crossref","first-page":"2530","DOI":"10.4103\/0366-6999.164983","article-title":"Apolipoprotein J: a new predictor and therapeutic target in cardiovascular disease?","volume":"128","author":"Yang","year":"2015","journal-title":"Chin Med J (Engl)"},{"issue":"1","key":"10.1016\/j.plipres.2025.101343_bb0645","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1042\/BJ20051190","article-title":"Up-regulation of the clusterin gene after proteotoxic stress: implication of HSF1-HSF2 heterocomplexes","volume":"395","author":"Loison","year":"2006","journal-title":"Biochem J"},{"issue":"6","key":"10.1016\/j.plipres.2025.101343_bb0650","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1159\/000351207","article-title":"The molecular chaperone apolipoprotein J\/clusterin as a sensor of oxidative stress: implications in therapeutic approaches - a mini-review","volume":"59","author":"Trougakos","year":"2013","journal-title":"Gerontology"},{"issue":"4","key":"10.1016\/j.plipres.2025.101343_bb0655","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1161\/01.ATV.18.4.665","article-title":"Distribution and synthesis of apolipoprotein J in the atherosclerotic aorta","volume":"18","author":"Ishikawa","year":"1998","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"1","key":"10.1016\/j.plipres.2025.101343_bb0660","first-page":"110","article-title":"Potential protective role of apoprotein J (clusterin) in atherogenesis: binding to enzymatically modified low-density lipoprotein reduces fatty acid-mediated cytotoxicity","volume":"100","author":"Schwarz","year":"2008","journal-title":"Thromb Haemost"},{"issue":"7","key":"10.1016\/j.plipres.2025.101343_bb0665","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1161\/01.ATV.17.7.1233","article-title":"Increased immunolocalization of paraoxonase, clusterin, and apolipoprotein A-I in the human artery wall with the progression of atherosclerosis","volume":"17","author":"Mackness","year":"1997","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"24","key":"10.1016\/j.plipres.2025.101343_bb0670","doi-asserted-by":"crossref","first-page":"7464","DOI":"10.1021\/bi962895r","article-title":"Potent inhibition of terminal complement assembly by clusterin: characterization of its impact on C9 polymerization","volume":"36","author":"McDonald","year":"1997","journal-title":"Biochemistry"},{"issue":"12","key":"10.1016\/j.plipres.2025.101343_bb0675","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1161\/hc3701.095583","article-title":"Apolipoprotein J\/clusterin is induced in vascular smooth muscle cells after vascular injury","volume":"104","author":"Miyata","year":"2001","journal-title":"Circulation"},{"issue":"4","key":"10.1016\/j.plipres.2025.101343_bb0680","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1067\/mva.2001.116301","article-title":"Apolipoprotein J inhibits the migration, adhesion, and proliferation of vascular smooth muscle cells","volume":"34","author":"Sivamurthy","year":"2001","journal-title":"J Vasc Surg"},{"issue":"3","key":"10.1016\/j.plipres.2025.101343_bb0685","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.dadm.2016.06.005","article-title":"Plasma clusterin levels and risk of dementia, Alzheimer\u2019s disease, and stroke","author":"Weinstein","year":"2016","journal-title":"Alzheimers Dement (Amst)"},{"issue":"46","key":"10.1016\/j.plipres.2025.101343_bb0690","doi-asserted-by":"crossref","first-page":"40083","DOI":"10.1074\/jbc.M111.252957","article-title":"CRM1 protein-mediated regulation of nuclear clusterin (nCLU), an ionizing radiation-stimulated, Bax-dependent pro-death factor","volume":"286","author":"Leskov","year":"2011","journal-title":"J Biol Chem"},{"issue":"44","key":"10.1016\/j.plipres.2025.101343_bb0695","doi-asserted-by":"crossref","first-page":"31286","DOI":"10.1074\/jbc.274.44.31286","article-title":"A novel human apolipoprotein (apoM)","volume":"274","author":"Xu","year":"1999","journal-title":"J Biol Chem"},{"key":"10.1016\/j.plipres.2025.101343_bb0700","doi-asserted-by":"crossref","unstructured":"Christoffersen, C, Nielsen, LB, Axler, O, Andersson, A, Johnsen, AH, Dahlb\u00e4ck, B. Isolation and characterization of human apolipoprotein M-containing lipoproteins. J Lipid Res. 2006 Aug;47(8):1833\u201343. https:\/\/doi.org\/10.1194\/jlr.M600055-JLR200. Epub 2006 May 8. 16682745.","DOI":"10.1194\/jlr.M600055-JLR200"},{"issue":"1","key":"10.1016\/j.plipres.2025.101343_bb0705","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1186\/s12872-019-1263-4","article-title":"Apolipoprotein M and sphingosine-1-phosphate complex alleviates TNF-\u03b1-induced endothelial cell injury and inflammation through PI3K\/AKT signaling pathway","volume":"19","author":"Liu","year":"2019","journal-title":"BMC Cardiovasc Disord"},{"issue":"7","key":"10.1016\/j.plipres.2025.101343_bb0710","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1016\/j.bbalip.2013.04.009","article-title":"Apolipoprotein M promotes mobilization of cellular cholesterol in vivo","volume":"1831","author":"Els\u00f8e","year":"2013","journal-title":"Biochim Biophys Acta"},{"issue":"2","key":"10.1016\/j.plipres.2025.101343_bb0715","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.3892\/mmr.2015.3658","article-title":"Apolipoprotein M: research progress, regulation and metabolic functions (review)","volume":"12","author":"Huang","year":"2015","journal-title":"Mol Med Rep"},{"key":"10.1016\/j.plipres.2025.101343_bb0720","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.atherosclerosis.2021.08.039","article-title":"Apolipoprotein M and its impact on endothelial dysfunction and inflammation in the cardiovascular system","volume":"334","author":"Yao Mattisson","year":"2021","journal-title":"Atherosclerosis"},{"issue":"13","key":"10.1016\/j.plipres.2025.101343_bb0725","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1161\/CIRCULATIONAHA.105.607135","article-title":"High-density lipoproteins and their constituent, sphingosine-1-phosphate, directly protect the heart against ischemia\/reperfusion injury in vivo via the S1P3 lysophospholipid receptor","volume":"114","author":"Theilmeier","year":"2006","journal-title":"Circulation"},{"issue":"6","key":"10.1016\/j.plipres.2025.101343_bb0730","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1055\/s-0038-1641750","article-title":"Apolipoprotein M protects lipopolysaccharide-treated mice from death and organ injury","volume":"118","author":"Kurano","year":"2018","journal-title":"Thromb Haemost"},{"issue":"4","key":"10.1016\/j.plipres.2025.101343_bb0735","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1038\/nm1211","article-title":"Apolipoprotein M is required for prebeta-HDL formation and cholesterol efflux to HDL and protects against atherosclerosis","volume":"11","author":"Wolfrum","year":"2005","journal-title":"Nat Med"},{"issue":"10","key":"10.1016\/j.plipres.2025.101343_bb0740","doi-asserted-by":"crossref","first-page":"e468","DOI":"10.1161\/ATVBAHA.121.316725","article-title":"Apolipoprotein M and sphingosine-1-phosphate receptor 1 promote the transendothelial transport of high-density lipoprotein","volume":"41","author":"Velagapudi","year":"2021","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"4","key":"10.1016\/j.plipres.2025.101343_bb0745","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.1074\/jbc.M704576200","article-title":"Effect of apolipoprotein M on high density lipoprotein metabolism and atherosclerosis in low density lipoprotein receptor knock-out mice","volume":"283","author":"Christoffersen","year":"2008","journal-title":"J Biol Chem"},{"issue":"1","key":"10.1016\/j.plipres.2025.101343_bb0750","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/s12944-017-0429-2","article-title":"HDL-associated ApoM is anti-apoptotic by delivering sphingosine 1-phosphate to S1P1 and S1P3 receptors on vascular endothelium","volume":"16","author":"Ruiz","year":"2017","journal-title":"Lipids Health Dis"},{"issue":"3","key":"10.1016\/j.plipres.2025.101343_bb0755","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1093\/cvr\/cvw004","article-title":"Sphingosine-1-phosphate reduces ischaemia-reperfusion injury by phosphorylating the gap junction protein Connexin43","volume":"109","author":"Morel","year":"2016","journal-title":"Cardiovasc Res"},{"issue":"3","key":"10.1016\/j.plipres.2025.101343_bb0760","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1007\/s12031-010-9453-7","article-title":"Association of apolipoprotein M gene polymorphisms with ischemic stroke in a Han Chinese population","volume":"43","author":"Zhao","year":"2011","journal-title":"J Mol Neurosci"},{"issue":"1","key":"10.1016\/j.plipres.2025.101343_bb0765","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1038\/s41598-023-27459-w","article-title":"Exploring the hub mechanisms of ischemic stroke based on protein-protein interaction networks related to ischemic stroke and inflammatory bowel disease","volume":"13","author":"Hu","year":"2023","journal-title":"Sci Rep"},{"issue":"10","key":"10.1016\/j.plipres.2025.101343_bb0770","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1161\/CIRCRESAHA.120.316526","article-title":"High-density lipoprotein carries markers that track with recovery from stroke","volume":"127","author":"Plubell","year":"2020","journal-title":"Circ Res"},{"key":"10.1016\/j.plipres.2025.101343_bb0775","doi-asserted-by":"crossref","DOI":"10.1111\/j.1365-2796.2005.01556.x","article-title":"Apolipoprotein B: a clinically important apolipoprotein which assembles atherogenic lipoproteins and promotes the development of atherosclerosis","author":"Olofsson","year":"2005","journal-title":"J Intern Med"},{"key":"10.1016\/j.plipres.2025.101343_bb0780","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1146\/annurev.nutr.20.1.169","article-title":"APOLIPOPROTEIN B: mRNA editing, lipoprotein assembly, and presecretory degradation","volume":"20","author":"Davidson","year":"2000","journal-title":"Annu Rev Nutr"},{"issue":"1","key":"10.1016\/j.plipres.2025.101343_bb0785","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1161\/CIRCULATIONAHA.124.068885","article-title":"Apolipoprotein B: bridging the gap between evidence and clinical practice","volume":"150","author":"De Oliveira-Gomes","year":"2024","journal-title":"Circulation"},{"issue":"6090","key":"10.1016\/j.plipres.2025.101343_bb0790","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1038\/323734a0","article-title":"Complete protein sequence and identification of structural domains of human apolipoprotein B","volume":"323","author":"Knott","year":"1986","journal-title":"Nature"},{"key":"10.1016\/j.plipres.2025.101343_bb0795","series-title":"Clinical Lipidology: A Companion to Braunwald\u2019s Heart Disease Ch. 2","first-page":"11","author":"Fazio","year":"2009"},{"key":"10.1016\/j.plipres.2025.101343_bb0800","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1126\/science.3283935","article-title":"Apolipoprotein E: cholesterol transport protein with expanding role in cell biology","volume":"240","author":"Mahley","year":"1988","journal-title":"Science"},{"issue":"2","key":"10.1016\/j.plipres.2025.101343_bb0805","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.jacc.2016.10.057","article-title":"Oxidized phospholipids on apolipoprotein B-100 and recurrent ischemic events following stroke or transient ischemic attack","volume":"69","author":"Byun","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.plipres.2025.101343_bb0810","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.122.025858","article-title":"Physiological bases for the superiority of apolipoprotein B over low-density lipoprotein cholesterol and non-high-density lipoprotein cholesterol as a marker of cardiovascular risk","volume":"11","author":"Glavinovic","year":"2022","journal-title":"J Am Heart Assoc"},{"issue":"2","key":"10.1016\/j.plipres.2025.101343_bb0815","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1177\/23969873231221619","article-title":"Discordance between LDL-C and apolipoprotein B is associated with large-artery-atherosclerosis ischemic stroke in patients \u2a7d70years of age","volume":"9","author":"Kriemler","year":"2024","journal-title":"Eur Stroke J"},{"issue":"1","key":"10.1016\/j.plipres.2025.101343_bb0820","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","article-title":"2019 ESC\/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk","volume":"41","author":"Mach","year":"2020","journal-title":"Eur Heart J"},{"key":"10.1016\/j.plipres.2025.101343_bb0825","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1016\/j.atherosclerosis.2012.08.039","article-title":"Discordance analysis of apolipoprotein B and non-high density lipoprotein cholesterol as markers of cardiovascular risk in the INTERHEART study","volume":"225","author":"Sniderman","year":"2012","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.plipres.2025.101343_bb0830","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.jacc.2015.10.055","article-title":"Discordance between apolipoprotein B and LDL-cholesterol in young adults predicts coronary artery calcification: the CARDIA study","volume":"67","author":"Wilkins","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.plipres.2025.101343_bb0835","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2023.106873","article-title":"Apolipoprotein B compared with low-density lipoprotein cholesterol in the atherosclerotic cardiovascular diseases risk assessment","volume":"195","author":"Galimberti","year":"2023","journal-title":"Pharmacol Res"},{"key":"10.1016\/j.plipres.2025.101343_bb0840","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1161\/CIRCULATIONAHA.121.057807","article-title":"ODYSSEY OUTCOMES Investigators. Apolipoprotein B, residual cardiovascular risk after acute cor- onary syndrome, and effects of alirocumab","volume":"146","author":"Hagstr\u00f6m","year":"2022","journal-title":"Circulation"},{"key":"10.1016\/j.plipres.2025.101343_bb0845","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1177\/2047487319871733","article-title":"Association of lowering apolipopro- tein B with cardiovascular outcomes across various lipid-lowering thera- pies: systematic review and meta-analysis of trials","volume":"27","author":"Khan","year":"2020","journal-title":"Eur J Prev Cardiol"},{"issue":"6661","key":"10.1016\/j.plipres.2025.101343_bb0850","doi-asserted-by":"crossref","DOI":"10.1126\/science.adh5207","article-title":"Intracellular tPA\u2013PAI-1 interaction determines VLDL assembly in hepatocytes","volume":"381","author":"Dai","year":"2023","journal-title":"Science"},{"issue":"1","key":"10.1016\/j.plipres.2025.101343_bb0855","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1161\/01.ATV.17.1.149","article-title":"Possible functional interactions of apolipoprotein B-100 segments that associate with cell proteoglycans and the ApoB\/E receptor","volume":"17","author":"Olsson","year":"1997","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"4","key":"10.1016\/j.plipres.2025.101343_bb0860","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.atherosclerosissup.2006.05.004","article-title":"The apolipoprotein story","volume":"7","author":"Sacks","year":"2006","journal-title":"Atherosclerosis Suppl"},{"key":"10.1016\/j.plipres.2025.101343_bb0865","doi-asserted-by":"crossref","first-page":"1832","DOI":"10.1161\/CIRCULATIONAHA.106.676890","article-title":"Subendothelial lipoprotein retention as the initiating process in atherosclerosis: update and therapeutic implications","volume":"116","author":"Tabas","year":"2007","journal-title":"Circulation"},{"key":"10.1016\/j.plipres.2025.101343_bb0870","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1007\/978-1-60327-029-8_24","article-title":"Oxidized low- density lipoprotein","volume":"610","author":"Parthasarathy","year":"2010","journal-title":"Methods Mol Biol"},{"issue":"14","key":"10.1016\/j.plipres.2025.101343_bb0875","first-page":"915","article-title":"Beyond cholesterol. Modifications of low-density lipoprotein that increase its atherogenicity","volume":"320","author":"Steinberg","year":"1989","journal-title":"N Engl J Med"},{"key":"10.1016\/j.plipres.2025.101343_bb0880","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1042\/BJ20150844","article-title":"The arterial microenvironment: the where and why of atherosclerosis","volume":"473","author":"Yurdagul","year":"2016","journal-title":"Biochem J"},{"key":"10.1016\/j.plipres.2025.101343_bb0885","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1001\/jamacardio.2019.3780","article-title":"Apolipoprotein B particles and cardiovascular disease: a narrative review","volume":"4","author":"Sniderman","year":"2019","journal-title":"JAMA Cardiol"},{"issue":"12","key":"10.1016\/j.plipres.2025.101343_bb0890","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1055\/s-0039-1696713","article-title":"Apolipoprotein B100\/low-density lipoprotein regulates proteolysis and functions of von Willebrand factor under arterial shear","volume":"119","author":"Cao","year":"2019","journal-title":"Thromb Haemost"},{"issue":"13","key":"10.1016\/j.plipres.2025.101343_bb0895","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1182\/blood.2023019749","article-title":"Low-density lipoprotein promotes microvascular thrombosis by enhancing von Willebrand factor self-association","volume":"142","author":"Chung","year":"2023","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.plipres.2025.101343_bb0900","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1016\/j.jacl.2016.09.009","article-title":"Familial defective apolipoprotein B-100: a review","volume":"10","author":"Andersen","year":"2016","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.plipres.2025.101343_bb0905","doi-asserted-by":"crossref","DOI":"10.1194\/jlr.RA120000919","article-title":"Distinct patterns of apolipoprotein C-I, C-II, and C-III isoforms are associated with markers of Alzheimer\u2019s disease","volume":"62","author":"Hu","year":"2021","journal-title":"J Lipid Res"},{"issue":"1","key":"10.1016\/j.plipres.2025.101343_bb0910","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/S0022-2275(20)37642-2","article-title":"Apolipoprotein A-I\/C-III\/A-IV gene cluster in familial combined hyperlipidemia: effects on LDL-cholesterol and apolipoproteins B and C-III","volume":"37","author":"Dallinga-Thie","year":"1996","journal-title":"J Lipid Res"},{"issue":"2","key":"10.1016\/j.plipres.2025.101343_bb0915","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1007\/BF00283370","article-title":"Localization of genes encoding apolipoproteins CI, CII, and E to the p13----cen region of human chromosome 19","volume":"71","author":"Scott","year":"1985","journal-title":"Hum Genet"},{"issue":"4","key":"10.1016\/j.plipres.2025.101343_bb0920","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/j.jacl.2015.05.002","article-title":"The risk of cardiovascular events with increased apolipoprotein CIII: a systematic review and meta-analysis","volume":"9","author":"Wyler von Ballmoos","year":"2015","journal-title":"J Clin Lipidol"},{"issue":"8","key":"10.1016\/j.plipres.2025.101343_bb0925","doi-asserted-by":"crossref","first-page":"2242","DOI":"10.1002\/pmic.200300809","article-title":"ApoC-I and ApoC-III as potential plasmatic markers to distinguish between ischemic and hemorrhagic stroke","volume":"4","author":"Allard","year":"2004","journal-title":"Proteomics"},{"issue":"3\u20134","key":"10.1016\/j.plipres.2025.101343_bb0930","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1002\/prca.201100041","article-title":"Discrimination of ischemic and hemorrhagic strokes using a multiplexed, mass spectrometry-based assay for serum apolipoproteins coupled to multi-marker ROC algorithm","volume":"6","author":"Lopez","year":"2012","journal-title":"PROTEOMICS \u2013 Clinical Applications"},{"issue":"7","key":"10.1016\/j.plipres.2025.101343_bb0935","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1016\/j.jacc.2016.11.065","article-title":"Very-low-density lipoprotein-associated apolipoproteins predict cardiovascular events and are lowered by inhibition of APOC-III","volume":"69","author":"Pechlaner","year":"2017","journal-title":"J Am Coll Cardiol"},{"issue":"23","key":"10.1016\/j.plipres.2025.101343_bb0940","doi-asserted-by":"crossref","first-page":"5939","DOI":"10.3390\/ijms20235939","article-title":"Apolipoprotein C1: its pleiotropic effects in lipid metabolism and beyond","volume":"20","author":"Fuior","year":"2019","journal-title":"Int J Mol Sci"},{"issue":"10","key":"10.1016\/j.plipres.2025.101343_bb0945","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.1194\/jlr.M200055-JLR200","article-title":"Plasma kinetics of VLDL and HDL apoC-I in normolipidemic and hypertriglyceridemic subjects","volume":"43","author":"Cohn","year":"2002","journal-title":"J Lipid Res"},{"issue":"2","key":"10.1016\/j.plipres.2025.101343_bb0950","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/0021-9150(86)90063-8","article-title":"Metabolism of apolipoprotein C-I in normolipoproteinemic human subjects","volume":"62","author":"Malmendier","year":"1986","journal-title":"Atherosclerosis"},{"issue":"45","key":"10.1016\/j.plipres.2025.101343_bb0955","doi-asserted-by":"crossref","first-page":"38108","DOI":"10.1074\/jbc.M504678200","article-title":"Molecular mechanism of the blockade of plasma cholesteryl ester transfer protein by its physiological inhibitor apolipoprotein CI","volume":"280","author":"Dumont","year":"2005","journal-title":"J Biol Chem"},{"issue":"48","key":"10.1016\/j.plipres.2025.101343_bb0960","doi-asserted-by":"crossref","first-page":"37504","DOI":"10.1074\/jbc.M007210200","article-title":"Human apolipoprotein C-I accounts for the ability of plasma high density lipoproteins to inhibit the cholesteryl ester transfer protein activity","volume":"275","author":"Gautier","year":"2000","journal-title":"J Biol Chem"},{"issue":"10","key":"10.1016\/j.plipres.2025.101343_bb0965","doi-asserted-by":"crossref","first-page":"6369","DOI":"10.1016\/S0021-9258(20)82151-6","article-title":"Discoidal complexes of a and C apolipoproteins with lipids and their reactions with lecithin: cholesterol acyltransferase","volume":"259","author":"Jonas","year":"1984","journal-title":"J Biol Chem"},{"issue":"1","key":"10.1016\/j.plipres.2025.101343_bb0970","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1186\/s12933-022-01703-5","article-title":"Role of apolipoprotein C1 in lipoprotein metabolism, atherosclerosis and diabetes: a systematic review","volume":"21","author":"Rouland","year":"2022","journal-title":"Cardiovasc Diabetol"},{"issue":"7","key":"10.1016\/j.plipres.2025.101343_bb0975","doi-asserted-by":"crossref","first-page":"1927","DOI":"10.1194\/jlr.M037531","article-title":"Changes in helical content or net charge of apolipoprotein C-I alter its affinity for lipid\/water interfaces","volume":"54","author":"Meyers","year":"2013","journal-title":"J Lipid Res"},{"issue":"7","key":"10.1016\/j.plipres.2025.101343_bb0980","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1161\/01.ATV.15.7.963","article-title":"Modulation of lipoprotein B binding to the LDL receptor by exogenous lipids and apolipoproteins CI, CII, CIII, and E","volume":"15","author":"Clavey","year":"1995","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"7","key":"10.1016\/j.plipres.2025.101343_bb0985","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1038\/sj.ki.5002449","article-title":"Hemodialysis reduces plasma apolipoprotein C-I concentration making VLDL a better substrate for lipoprotein lipase","volume":"72","author":"Dautin","year":"2007","journal-title":"Kidney Int"},{"issue":"9","key":"10.1016\/j.plipres.2025.101343_bb0990","doi-asserted-by":"crossref","first-page":"1842","DOI":"10.1194\/jlr.M800588-JLR200","article-title":"Apolipoprotein CI is a physiological regulator of cholesteryl ester transfer protein activity in human plasma but not in rabbit plasma","volume":"50","author":"de Barros","year":"2009","journal-title":"J Lipid Res"},{"issue":"Pt 2","key":"10.1016\/j.plipres.2025.101343_bb0995","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1042\/bj3380281","article-title":"Reversal of hyperlipidaemia in apolipoprotein C1 transgenic mice by adenovirus-mediated gene delivery of the low-density-lipoprotein receptor, but not by the very-low-density-lipoprotein receptor","volume":"338","author":"Jong","year":"1999","journal-title":"Biochem J"},{"issue":"47","key":"10.1016\/j.plipres.2025.101343_bb1000","doi-asserted-by":"crossref","first-page":"33997","DOI":"10.1074\/jbc.M113.495366","article-title":"Apolipoproteins C-I and C-III inhibit lipoprotein lipase activity by displacement of the enzyme from lipid droplets","volume":"288","author":"Larsson","year":"2013","journal-title":"J Biol Chem"},{"issue":"6","key":"10.1016\/j.plipres.2025.101343_bb1005","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1194\/jlr.M022988","article-title":"Constitutive inhibition of plasma CETP by apolipoprotein C1 is blunted in dyslipidemic patients with coronary artery disease","volume":"53","author":"Pillois","year":"2012","journal-title":"J Lipid Res"},{"key":"10.1016\/j.plipres.2025.101343_bb1010","doi-asserted-by":"crossref","first-page":"e56","DOI":"10.15420\/ecr.2023.16","article-title":"The role of triglyceride-rich lipoproteins and their remnants in atherosclerotic cardiovascular disease","volume":"18","author":"Gabani","year":"2023","journal-title":"Eur Cardiol"},{"issue":"5","key":"10.1016\/j.plipres.2025.101343_bb1015","doi-asserted-by":"crossref","first-page":"1942","DOI":"10.1073\/pnas.74.5.1942","article-title":"Primary structure of very low density apolipoprotein C-II of human plasma","volume":"74","author":"Jackson","year":"1977","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.plipres.2025.101343_bb1020","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.atherosclerosis.2017.10.025","article-title":"Apolipoprotein C-II: New findings related to genetics, biochemistry, and role in triglyceride metabolism","volume":"267","author":"Wolska","year":"2017","journal-title":"Atherosclerosis"},{"issue":"3","key":"10.1016\/j.plipres.2025.101343_bb1025","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1097\/MOL.0000000000000680","article-title":"Apolipoprotein C-II: the re-emergence of a forgotten factor","volume":"31","author":"Wolska","year":"2020","journal-title":"Curr Opin Lipidol"},{"issue":"7","key":"10.1016\/j.plipres.2025.101343_bb1030","doi-asserted-by":"crossref","first-page":"1872","DOI":"10.1021\/bi0267184","article-title":"Global structure and dynamics of human apolipoprotein CII in complex with micelles: evidence for increased mobility of the helix involved in the activation of lipoprotein lipase","volume":"42","author":"Zdunek","year":"2003","journal-title":"Biochemistry"},{"issue":"18","key":"10.1016\/j.plipres.2025.101343_bb1035","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2221888120","article-title":"Inverse effects of APOC2 and ANGPTL4 on the conformational dynamics of lid-anchoring structures in lipoprotein lipase","volume":"120","author":"Kumari","year":"2023","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"10","key":"10.1016\/j.plipres.2025.101343_bb1040","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1016\/S0022-2275(20)35742-4","article-title":"Abnormal activation of lipoprotein lipase by non-equilibrating apoC-II: further evidence for the presence of non-equilibrating pools of apolipoproteins C-II and C-III in plasma lipoproteins","volume":"34","author":"Tornoci","year":"1993","journal-title":"J Lipid Res"},{"key":"10.1016\/j.plipres.2025.101343_bb1045","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2020.154296","article-title":"ApoC2 deficiency elicits severe hypertriglyceridemia and spontaneous atherosclerosis: a rodent model rescued from neonatal death","volume":"109","author":"Gao","year":"2020","journal-title":"Metabolism"},{"issue":"1","key":"10.1016\/j.plipres.2025.101343_bb1050","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/s102380200003","article-title":"A case of apolipoprotein C-II deficiency with coronary artery disease","volume":"2","author":"Kawano","year":"2002","journal-title":"Clin Exp Med"},{"issue":"7","key":"10.1016\/j.plipres.2025.101343_bb1055","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1016\/j.metabol.2011.12.002","article-title":"A review of the role of apolipoprotein C-II in lipoprotein metabolism and cardiovascular disease","volume":"61","author":"Kei","year":"2012","journal-title":"Metabolism"},{"key":"10.1016\/j.plipres.2025.101343_bb1060","doi-asserted-by":"crossref","first-page":"625","DOI":"10.2147\/CLEP.S196266","article-title":"Association of apolipoproteins C-I, C-II, C-III and E with coagulation markers and venous thromboembolism risk","volume":"11","author":"Orsi","year":"2019","journal-title":"Clin Epidemiol"},{"issue":"7","key":"10.1016\/j.plipres.2025.101343_bb1065","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1161\/ATVBAHA.107.160192","article-title":"Overproduction of very low-density lipoproteins is the hallmark of the dyslipidemia in the metabolic syndrome","volume":"28","author":"Adiels","year":"2008","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"1","key":"10.1016\/j.plipres.2025.101343_bb1070","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1006\/pmed.2002.1045","article-title":"Association between serum apolipoprotein C(II) concentration and coronary heart disease","volume":"35","author":"Gerber","year":"2002","journal-title":"Prev Med"},{"issue":"8","key":"10.1016\/j.plipres.2025.101343_bb1075","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1111\/eci.12657","article-title":"Triglyceride-rich lipoprotein metabolism in women: roles of apoC-II and apoC-III","volume":"46","author":"Ooi","year":"2016","journal-title":"Eur J Clin Invest"},{"issue":"9","key":"10.1016\/j.plipres.2025.101343_bb1080","doi-asserted-by":"crossref","first-page":"2257","DOI":"10.2337\/db11-0040","article-title":"Increased VLDL-triglyceride secretion precedes impaired control of endogenous glucose production in obese, normoglycemic men","volume":"60","author":"S\u00f8rensen","year":"2011","journal-title":"Diabetes"},{"issue":"25","key":"10.1016\/j.plipres.2025.101343_bb1085","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.1093\/eurheartj\/ehad261","article-title":"Inverse association between apolipoprotein C-II and cardiovascular mortality: role of lipoprotein lipase activity modulation","volume":"44","author":"Silbernagel","year":"2023","journal-title":"Eur Heart J"},{"issue":"10","key":"10.1016\/j.plipres.2025.101343_bb1090","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/j.tips.2015.07.001","article-title":"Apolipoprotein C-III: from pathophysiology to pharmacology","volume":"36","author":"Norata","year":"2015","journal-title":"Trends Pharmacol Sci"},{"key":"10.1016\/j.plipres.2025.101343_bb1095","doi-asserted-by":"crossref","DOI":"10.1016\/j.jprot.2021.104398","article-title":"Distribution of seven ApoC-III glycoforms in plasma, VLDL, IDL, LDL and HDL of healthy subjects","volume":"251","author":"Rodr\u00edguez","year":"2022","journal-title":"J Proteomics"},{"issue":"3","key":"10.1016\/j.plipres.2025.101343_bb1100","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1007\/s11883-023-01080-8","article-title":"APOC-III: a Gatekeeper in Controlling Triglyceride Metabolism","volume":"25","author":"Giammanco","year":"2023","journal-title":"Curr Atheroscler Rep"},{"issue":"15","key":"10.1016\/j.plipres.2025.101343_bb1105","doi-asserted-by":"crossref","first-page":"1722","DOI":"10.1161\/CIRCULATIONAHA.109.875807","article-title":"Apolipoprotein C-III and the metabolic basis for hypertriglyceridemia and the dense low-density lipoprotein phenotype","volume":"121","author":"Zheng","year":"2010","journal-title":"Circulation"},{"issue":"8","key":"10.1016\/j.plipres.2025.101343_bb1110","doi-asserted-by":"crossref","first-page":"2855","DOI":"10.1172\/JCI86610","article-title":"ApoC-III inhibits clearance of triglyceride-rich lipoproteins through LDL family receptors","volume":"126","author":"Gordts","year":"2016","journal-title":"J Clin Invest"},{"issue":"4","key":"10.1016\/j.plipres.2025.101343_bb1115","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.98045","article-title":"Apolipoproteins E and CIII interact to regulate HDL metabolism and coronary heart disease risk","volume":"3","author":"Morton","year":"2018","journal-title":"JCI Insight"},{"issue":"1","key":"10.1016\/j.plipres.2025.101343_bb1120","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1097\/MOL.0000000000000146","article-title":"The crucial roles of apolipoproteins E and C-III in apoB lipoprotein metabolism in normolipidemia and hypertriglyceridemia","volume":"26","author":"Sacks","year":"2015","journal-title":"Curr Opin Lipidol"},{"issue":"10","key":"10.1016\/j.plipres.2025.101343_bb1125","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1016\/S0022-2275(20)32211-2","article-title":"Apolipoprotein C-III deficiency accelerates triglyceride hydrolysis by lipoprotein lipase in wild-type and apoE knockout mice","volume":"42","author":"Jong","year":"2001","journal-title":"J Lipid Res"},{"issue":"8","key":"10.1016\/j.plipres.2025.101343_bb1130","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1373\/clinchem.2008.103234","article-title":"Increased plasma apolipoprotein C-III concentration independently predicts cardiovascular mortality: the Hoorn Study","volume":"54","author":"Scheffer","year":"2008","journal-title":"Clin Chem"},{"issue":"6","key":"10.1016\/j.plipres.2025.101343_bb1135","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1161\/ATVBAHA.117.309007","article-title":"Apolipoprotein C-III levels and incident coronary artery disease risk: the EPIC-Norfolk prospective population study","volume":"37","author":"van Capelleveen","year":"2017","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.plipres.2025.101343_bb1140","article-title":"ApoCIII: a multifaceted protein in cardiometabolic disease","volume":"113","author":"D\u2019Erasmo","year":"2020","journal-title":"Metabolism"},{"issue":"2","key":"10.1016\/j.plipres.2025.101343_bb1145","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1161\/ATVBAHA.109.197830","article-title":"Metabolism of very-low-density lipoprotein and low-density lipoprotein containing apolipoprotein C-III and not other small apolipoproteins","volume":"30","author":"Mendivil","year":"2010","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"3","key":"10.1016\/j.plipres.2025.101343_bb1150","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1097\/MOL.0000000000000502","article-title":"Apolipoprotein C-III in triglyceride-rich lipoprotein metabolism","volume":"29","author":"Ramms","year":"2018","journal-title":"Curr Opin Lipidol"},{"issue":"6","key":"10.1016\/j.plipres.2025.101343_bb1155","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1161\/CIRCGENETICS.113.000369","article-title":"Rare variant APOC3 R19X is associated with cardio-protective profiles in a diverse population-based survey as part of the Epidemiologic Architecture for Genes Linked to Environment Study","volume":"7","author":"Crawford","year":"2014","journal-title":"Circ Cardiovasc Genet"},{"issue":"1","key":"10.1016\/j.plipres.2025.101343_bb1160","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1056\/NEJMoa1308027","article-title":"Loss-of-function mutations in APOC3 and risk of ischemic vascular disease","volume":"371","author":"J\u00f8rgensen","year":"2014","journal-title":"N Engl J Med"},{"issue":"5908","key":"10.1016\/j.plipres.2025.101343_bb1165","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.1126\/science.1161524","article-title":"A null mutation in human APOC3 confers a favorable plasma lipid profile and apparent cardioprotection","volume":"322","author":"Pollin","year":"2008","journal-title":"Science"},{"issue":"1","key":"10.1016\/j.plipres.2025.101343_bb1170","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1161\/ATVBAHA.118.311476","article-title":"Effects of APOC3 heterozygous deficiency on plasma lipid and lipoprotein metabolism","volume":"39","author":"Reyes-Soffer","year":"2019","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"3","key":"10.1016\/j.plipres.2025.101343_bb1175","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1161\/ATVBAHA.117.310473","article-title":"APOC3 loss-of-function mutations, remnant cholesterol, low-density lipoprotein cholesterol, and cardiovascular risk: mediation- and meta-analyses of 137 895 individuals","volume":"38","author":"Wulff","year":"2018","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"11","key":"10.1016\/j.plipres.2025.101343_bb1180","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1161\/CIRCRESAHA.111.300367","article-title":"Antisense oligonucleotide inhibition of apolipoprotein C-III reduces plasma triglycerides in rodents, nonhuman primates, and humans","volume":"112","author":"Graham","year":"2013","journal-title":"Circ Res"},{"issue":"4","key":"10.1016\/j.plipres.2025.101343_bb1185","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1093\/cvr\/cvv192","article-title":"Aggravated restenosis and atherogenesis in ApoCIII transgenic mice but lack of protection in ApoCIII knockouts: the effect of authentic triglyceride-rich lipoproteins with and without ApoCIII","volume":"107","author":"Li","year":"2015","journal-title":"Cardiovasc Res"},{"issue":"3","key":"10.1016\/j.plipres.2025.101343_bb1190","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.1111\/jcmm.16244","article-title":"Identification of biomarker panels as predictors of severity in coronary artery disease","volume":"25","author":"Ben Braiek","year":"2021","journal-title":"J Cell Mol Med"},{"issue":"2","key":"10.1016\/j.plipres.2025.101343_bb1195","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1055\/s-0038-1676817","article-title":"Apolipoprotein C-III strongly correlates with activated factor VII-anti-thrombin complex: an additional link between plasma lipids and coagulation","volume":"119","author":"Martinelli","year":"2019","journal-title":"Thromb Haemost"},{"issue":"6","key":"10.1016\/j.plipres.2025.101343_bb1200","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.113.000440","article-title":"Factor II activity is similarly increased in patients with elevated apolipoprotein CIII and in carriers of the factor II 20210A allele","volume":"2","author":"Olivieri","year":"2013","journal-title":"J Am Heart Assoc"},{"issue":"3","key":"10.1016\/j.plipres.2025.101343_bb1205","doi-asserted-by":"crossref","DOI":"10.3390\/ijms24032223","article-title":"CD14+-monocytes exposed to apolipoprotein CIII express tissue factor","volume":"24","author":"Olivieri","year":"2023","journal-title":"Int J Mol Sci"},{"issue":"13","key":"10.1016\/j.plipres.2025.101343_bb1210","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1161\/CIRCULATIONAHA.117.031276","article-title":"High-density lipoprotein subspecies defined by presence of apolipoprotein C-III and incident coronary heart disease in four cohorts","volume":"137","author":"Jensen","year":"2018","journal-title":"Circulation"},{"issue":"1","key":"10.1016\/j.plipres.2025.101343_bb1215","first-page":"61","article-title":"Apolipoprotein C-III in the high-density lipoprotein proteome of cerebral lacunar infarction patients impairs its anti-inflammatory function","volume":"41","author":"Lv","year":"2018","journal-title":"Int J Mol Med"},{"issue":"1","key":"10.1016\/j.plipres.2025.101343_bb1220","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.atherosclerosis.2009.11.022","article-title":"Apolipoprotein H: its relevance to cardiovascular disease","volume":"209","author":"Crook","year":"2010","journal-title":"Atherosclerosis"},{"issue":"2","key":"10.1016\/j.plipres.2025.101343_bb1225","doi-asserted-by":"crossref","DOI":"10.11613\/BM.2024.020504","article-title":"Antiphospholipid antibodies in patients with antiphospholipid syndrome","volume":"34","author":"Dodig","year":"2024","journal-title":"Biochem Med (Zagreb)"},{"issue":"12","key":"10.1016\/j.plipres.2025.101343_bb1230","doi-asserted-by":"crossref","first-page":"2648","DOI":"10.1194\/jlr.M800155-JLR200","article-title":"Comprehensive evaluation of apolipoprotein H gene (APOH) variation identifies novel associations with measures of lipid metabolism in GENOA","volume":"49","author":"Leduc","year":"2008","journal-title":"J Lipid Res"},{"issue":"5","key":"10.1016\/j.plipres.2025.101343_bb1235","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1016\/0026-0495(82)90238-4","article-title":"Studies on the possible function of beta 2-glycoprotein-I: influence in the triglyceride metabolism in the rat","volume":"31","author":"Wurm","year":"1982","journal-title":"Metabolism"},{"issue":"2","key":"10.1016\/j.plipres.2025.101343_bb1240","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.tibs.2006.12.008","article-title":"Molecular biology of PCSK9: its role in LDL metabolism","volume":"32","author":"Horton","year":"2007","journal-title":"Trends Biochem Sci"},{"issue":"1","key":"10.1016\/j.plipres.2025.101343_bb1245","article-title":"Identification of novel proteins interacting with proprotein convertase subtilisin\/kexin 9","volume":"3","author":"Melendez","year":"2020","journal-title":"Int J Biomed Investig"},{"key":"10.1016\/j.plipres.2025.101343_bb1250","doi-asserted-by":"crossref","DOI":"10.1016\/j.blre.2019.100610","article-title":"The role of beta-2-glycoprotein I in health and disease associating structure with function: More than just APS","volume":"39","author":"McDonnell","year":"2020","journal-title":"Blood Rev"},{"key":"10.1016\/j.plipres.2025.101343_bb1255","first-page":"234316","article-title":"Proatherogenic oxidized low-density lipoprotein\/\u03b22-glycoprotein I complexes in arterial and venous disease","author":"Berger","year":"2014","journal-title":"J Immunol Res"},{"issue":"10","key":"10.1016\/j.plipres.2025.101343_bb1260","doi-asserted-by":"crossref","first-page":"2815","DOI":"10.1194\/jlr.M040733","article-title":"Determinants of binding of oxidized phospholipids on apolipoprotein (a) and lipoprotein (a)","volume":"54","author":"Leibundgut","year":"2013","journal-title":"J Lipid Res"},{"key":"10.1016\/j.plipres.2025.101343_bb1265","doi-asserted-by":"crossref","DOI":"10.1155\/2014\/239398","article-title":"Revisiting the molecular mechanism of neurological manifestations in antiphospholipid syndrome: beyond vascular damage","volume":"2014","author":"Carecchio","year":"2014","journal-title":"J Immunol Res"},{"issue":"6","key":"10.1016\/j.plipres.2025.101343_bb1270","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1136\/annrheumdis-2013-204838","article-title":"Morbidity and mortality in the antiphospholipid syndrome during a 10-year period: a multicentre prospective study of 1000 patients","volume":"74","author":"Cervera","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.plipres.2025.101343_bb1275","doi-asserted-by":"crossref","DOI":"10.1177\/10760296221088576","article-title":"The pathophysiology of the antiphospholipid syndrome: a perspective from the blood coagulation system","volume":"28","author":"Arreola-Diaz","year":"2022","journal-title":"Clin Appl Thromb Hemost"},{"issue":"1","key":"10.1016\/j.plipres.2025.101343_bb1280","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1161\/ATVBAHA.120.314965","article-title":"Genome-wide association study highlights APOH as a novel locus for lipoprotein(a) levels-brief report","volume":"41","author":"Hoekstra","year":"2021","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.plipres.2025.101343_bb1285","doi-asserted-by":"crossref","first-page":"23675","DOI":"10.1038\/srep23675","article-title":"Genome-wide significant results identified for plasma apolipoprotein H levels in middle-aged and older adults","volume":"6","author":"Mather","year":"2016","journal-title":"Sci Rep"},{"issue":"47","key":"10.1016\/j.plipres.2025.101343_bb1290","doi-asserted-by":"crossref","first-page":"36289","DOI":"10.1074\/jbc.M510861200","article-title":"ApoO, a novel apolipoprotein, is an original glycoprotein up-regulated by diabetes in human heart","volume":"281","author":"Lamant","year":"2006","journal-title":"J Biol Chem"},{"issue":"4","key":"10.1016\/j.plipres.2025.101343_bb1295","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/j.bbalip.2011.01.008","article-title":"Overexpression of apolipoprotein O does not impact on plasma HDL levels or functionality in human apolipoprotein A-I transgenic mice","volume":"1811","author":"Nijstad","year":"2011","journal-title":"Biochim Biophys Acta"},{"issue":"9","key":"10.1016\/j.plipres.2025.101343_bb1300","doi-asserted-by":"crossref","first-page":"1952","DOI":"10.1194\/jlr.P023028","article-title":"Plasma apolipoprotein O level increased in the patients with acute coronary syndrome","volume":"53","author":"Yu","year":"2012","journal-title":"J Lipid Res"},{"key":"10.1016\/j.plipres.2025.101343_bb1305","doi-asserted-by":"crossref","DOI":"10.1016\/j.atherosclerosis.2023.117374","article-title":"Macrophage-specific deletion of MIC26 (APOO) mitigates advanced atherosclerosis by increasing efferocytosis","volume":"386","author":"Tang","year":"2023","journal-title":"Atherosclerosis"},{"issue":"2","key":"10.1016\/j.plipres.2025.101343_bb1310","doi-asserted-by":"crossref","DOI":"10.1093\/braincomms\/fcae091","article-title":"Predictive value of neutrophil to apolipoprotein A1 ratio in patients with acute ischaemic stroke","volume":"6","author":"Chen","year":"2024","journal-title":"Brain Commun"},{"issue":"4","key":"10.1016\/j.plipres.2025.101343_bb1315","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1161\/ATVBAHA.118.311857","article-title":"Lipoprotein(a) and risk of ischemic stroke in the REGARDS study","volume":"39","author":"Arora","year":"2019","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.plipres.2025.101343_bb1320","first-page":"27","article-title":"All we need to know about lipoprotein(a)","volume":"84","author":"Bess","year":"2024","journal-title":"Prog Cardiovasc Dis"},{"issue":"25","key":"10.1016\/j.plipres.2025.101343_bb1325","doi-asserted-by":"crossref","first-page":"2761","DOI":"10.1016\/j.jacc.2016.10.033","article-title":"Phenotypic characterization of genetically lowered human lipoprotein(a) levels","volume":"68","author":"Emdin","year":"2016","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"10.1016\/j.plipres.2025.101343_bb1330","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.jacc.2019.03.524","article-title":"Elevated lipoprotein(a) and risk of ischemic stroke","volume":"74","author":"Langsted","year":"2019","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"10.1016\/j.plipres.2025.101343_bb1335","doi-asserted-by":"crossref","first-page":"e48","DOI":"10.1161\/ATV.0000000000000147","volume":"42","author":"Reyes-Soffer","year":"2022","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.plipres.2025.101343_bb1340","doi-asserted-by":"crossref","first-page":"120738","DOI":"10.1016\/j.jns.2023.120738","article-title":"Association between lipoprotein(a) and ischemic stroke: fibrinogen as a mediator","volume":"452","author":"Youyou","year":"2023","journal-title":"J Neurol Sci"},{"issue":"17","key":"10.1016\/j.plipres.2025.101343_bb1345","doi-asserted-by":"crossref","first-page":"3229","DOI":"10.1021\/bi00767a015","article-title":"Protein and carbohydrate composition of Lp(a)lipoprotein from human plasma","volume":"11","author":"Ehnholm","year":"1972","journal-title":"Biochemistry"},{"issue":"8","key":"10.1016\/j.plipres.2025.101343_bb1350","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1161\/CIRCULATIONAHA.116.020838","article-title":"Oxidized phospholipids on lipoprotein(a) elicit arterial wall inflammation and an inflammatory monocyte response in humans","volume":"134","author":"van der Valk","year":"2016","journal-title":"Circulation"},{"issue":"7","key":"10.1016\/j.plipres.2025.101343_bb1355","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1016\/S2213-8587(17)30088-8","article-title":"Apolipoprotein(a) isoform size, lipoprotein(a) concentration, and coronary artery disease: a mendelian randomisation analysis","volume":"5","author":"Saleheen","year":"2017","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"2","key":"10.1016\/j.plipres.2025.101343_bb1360","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.jacc.2017.11.014","article-title":"NHLBI working group recommendations to reduce lipoprotein(a)-mediated risk of cardiovascular disease and aortic stenosis","volume":"71","author":"Tsimikas","year":"2018","journal-title":"J Am Coll Cardiol"},{"issue":"9","key":"10.1016\/j.plipres.2025.101343_bb1365","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1194\/jlr.M076232","article-title":"A genome-wide association meta-analysis on lipoprotein (a) concentrations adjusted for apolipoprotein (a) isoforms","volume":"58","author":"Mack","year":"2017","journal-title":"J Lipid Res"},{"issue":"8","key":"10.1016\/j.plipres.2025.101343_bb1370","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1194\/jlr.R067314","article-title":"Structure, function, and genetics of lipoprotein (a)","volume":"57","author":"Schmidt","year":"2016","journal-title":"J Lipid Res"},{"issue":"3","key":"10.1016\/j.plipres.2025.101343_bb1375","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.tips.2019.01.004","article-title":"New frontiers in Lp(a)-targeted therapies","volume":"40","author":"Borrelli","year":"2019","journal-title":"Trends Pharmacol Sci"},{"issue":"9","key":"10.1016\/j.plipres.2025.101343_bb1380","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1194\/jlr.R077693","article-title":"The metabolism of lipoprotein (a): an ever-evolving story","volume":"58","author":"Reyes-Soffer","year":"2017","journal-title":"J Lipid Res"},{"issue":"10","key":"10.1016\/j.plipres.2025.101343_bib1598","doi-asserted-by":"crossref","first-page":"3224","DOI":"10.1073\/pnas.84.10.3224","article-title":"Partial amino acid sequence of apolipoprotein(a) shows that it is homologous to plasminogen","volume":"84","author":"Eaton","year":"1987","journal-title":"Proc Natl Acad Sci USA"},{"issue":"5","key":"10.1016\/j.plipres.2025.101343_bb1385","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1038\/s41569-018-0153-2","article-title":"Oxidized phospholipids as a unifying theory for lipoprotein(a) and cardiovascular disease","author":"Boffa","year":"2019","journal-title":"Nat Rev Cardiol"},{"issue":"6222","key":"10.1016\/j.plipres.2025.101343_bb1390","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1038\/339303a0","article-title":"Lipoprotein(a) modulation of endothelial cell surface fibrinolysis and its potential role in atherosclerosis","volume":"339","author":"Hajjar","year":"1989","journal-title":"Nature"},{"issue":"7","key":"10.1016\/j.plipres.2025.101343_bb1395","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1097\/00019501-200111000-00008","article-title":"Increased plasminogen activator inhibitor-1 and apolipoprotein (a) in coronary atherectomy specimens in acute coronary syndromes","volume":"12","author":"Shindo","year":"2001","journal-title":"Coron Artery Dis"},{"issue":"4","key":"10.1016\/j.plipres.2025.101343_bib1602","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1194\/jlr.M036566","article-title":"Inhibition of plasminogen activation by apo(a): role of carboxyl-terminal lysines and identification of inhibitory domains in apo(a)","volume":"55","author":"Romagnuolo","year":"2014","journal-title":"J Lipid Res"},{"key":"10.1016\/j.plipres.2025.101343_bb1400","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.atherosclerosis.2022.04.009","article-title":"Beyond fibrinolysis: the confounding role of Lp(a) in thrombosis","volume":"349","author":"Boffa","year":"2022","journal-title":"Atherosclerosis"},{"issue":"1","key":"10.1016\/j.plipres.2025.101343_bb1405","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/S0002-9440(10)64366-0","article-title":"Lipoprotein(a) promotes smooth muscle cell proliferation and dedifferentiation in atherosclerotic lesions of human apo(a) transgenic rabbits","volume":"160","author":"Ichikawa","year":"2002","journal-title":"Am J Pathol"},{"issue":"1","key":"10.1016\/j.plipres.2025.101343_bb1410","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.cardiores.2004.03.005","article-title":"Effect of lipoprotein (a) on platelet activation induced by platelet-activating factor: role of apolipoprotein (a) and endogenous PAF-acetylhydrolase","volume":"63","author":"Tsironis","year":"2004","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.plipres.2025.101343_bb1415","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2023.1130162","article-title":"Lipoprotein(a) induces caspase-1 activation and IL-1 signaling in human macrophages","volume":"10","author":"Lorey","year":"2023","journal-title":"Front Cardiovasc Med"},{"key":"10.1016\/j.plipres.2025.101343_bb1420","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/S0065-3233(08)60642-7","article-title":"Apolipoprotein E: structure-function relationships","volume":"45","author":"Weisgraber","year":"1994","journal-title":"Adv Protein Chem"},{"issue":"2","key":"10.1016\/j.plipres.2025.101343_bb1425","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1093\/ije\/dyt034","article-title":"Apolipoprotein E genotype, cardiovascular biomarkers and risk of stroke: systematic review and meta-analysis of 14 015 stroke cases and pooled analysis of primary biomarker data from up to 60 883 individuals","volume":"42","author":"Khan","year":"2013","journal-title":"Int J Epidemiol"},{"issue":"1","key":"10.1016\/j.plipres.2025.101343_bb1430","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1002\/ajpa.21298","article-title":"Worldwide allele frequencies of the human apolipoprotein E gene: climate, local adaptations, and evolutionary history","volume":"143","author":"Eisenberg","year":"2010","journal-title":"Am J Phys Anthropol"},{"issue":"2","key":"10.1016\/j.plipres.2025.101343_bb1435","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1038\/nrneurol.2012.263","article-title":"Apolipoprotein E and Alzheimer disease: risk, mechanisms and therapy","volume":"9","author":"Liu","year":"2013","journal-title":"Nat Rev Neurol"},{"key":"10.1016\/j.plipres.2025.101343_bib1599","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.2147\/CIA.S131172","article-title":"Apolipoprotein \u03b57 allele in memory complaints: insights through protein structure prediction","volume":"12","author":"Youn","year":"2017","journal-title":"Clin Interv Aging"},{"issue":"9","key":"10.1016\/j.plipres.2025.101343_bb1440","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1038\/s41582-019-0228-7","article-title":"Apolipoprotein E and Alzheimer disease: pathobiology and targeting strategies","volume":"15","author":"Yamazaki","year":"2019","journal-title":"Nat Rev Neurol"},{"key":"10.1016\/j.plipres.2025.101343_bb1445","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.atherosclerosis.2016.10.037","article-title":"Plasma levels of apolipoprotein E, APOE genotype and risk of dementia and ischemic heart disease: a review","volume":"255","author":"Rasmussen","year":"2016","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.plipres.2025.101343_bb1450","doi-asserted-by":"crossref","DOI":"10.1016\/j.nbd.2020.104809","article-title":"Beyond the CNS: the many peripheral roles of APOE","volume":"138","author":"Mart\u00ednez-Mart\u00ednez","year":"2020","journal-title":"Neurobiol Dis"},{"issue":"4586","key":"10.1016\/j.plipres.2025.101343_bb1455","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1126\/science.6823554","article-title":"Independent pathways for secretion of cholesterol and apolipoprotein E by macrophages","volume":"219","author":"Basu","year":"1983","journal-title":"Science"},{"issue":"Suppl","key":"10.1016\/j.plipres.2025.101343_bb1460","doi-asserted-by":"crossref","first-page":"S156","DOI":"10.1194\/jlr.R800058-JLR200","article-title":"Apoprotein E as a lipid transport and signaling protein in the blood, liver, and artery wall","volume":"50","author":"Getz","year":"2009","journal-title":"J Lipid Res"},{"issue":"17","key":"10.1016\/j.plipres.2025.101343_bb1465","doi-asserted-by":"crossref","first-page":"9892","DOI":"10.3390\/ijms23179892","article-title":"Apolipoprotein E in Cardiometabolic and neurological health and diseases","volume":"23","author":"Alagarsamy","year":"2022","journal-title":"Int J Mol Sci"},{"issue":"1","key":"10.1016\/j.plipres.2025.101343_bb1470","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1074\/jbc.272.1.89","article-title":"Apolipoprotein E inhibits platelet aggregation through the L-arginine:nitric oxide pathway. Implications for vascular disease","volume":"272","author":"Riddell","year":"1997","journal-title":"J Biol Chem"},{"issue":"49","key":"10.1016\/j.plipres.2025.101343_bb1475","doi-asserted-by":"crossref","first-page":"46011","DOI":"10.1074\/jbc.M104812200","article-title":"Cell-derived apolipoprotein E (ApoE) particles inhibit vascular cell adhesion molecule-1 (VCAM-1) expression in human endothelial cells","volume":"276","author":"Stannard","year":"2001","journal-title":"J Biol Chem"},{"issue":"37","key":"10.1016\/j.plipres.2025.101343_bb1480","doi-asserted-by":"crossref","first-page":"13493","DOI":"10.1073\/pnas.1402106111","article-title":"Genetic variants of ApoE and ApoER2 differentially modulate endothelial function","volume":"111","author":"Ulrich","year":"2014","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"5","key":"10.1016\/j.plipres.2025.101343_bb1485","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1161\/ATVBAHA.111.222745","article-title":"Apolipoprotein E induces antiinflammatory phenotype in macrophages","volume":"31","author":"Baitsch","year":"2011","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"3","key":"10.1016\/j.plipres.2025.101343_bb1490","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1097\/00041433-200006000-00004","article-title":"Apolipoprotein E and atherosclerosis","volume":"11","author":"Curtiss","year":"2000","journal-title":"Curr Opin Lipidol"},{"issue":"15","key":"10.1016\/j.plipres.2025.101343_bb1495","article-title":"APOE and Alzheimer\u2019s disease: from lipid transport to physiopathology and therapeutics","author":"Husain","year":"2021","journal-title":"Front Neurosci"},{"key":"10.1016\/j.plipres.2025.101343_bb1500","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/j.tibs.2006.06.008","article-title":"Apolipoprotein E structure: insights into function","volume":"31","author":"Hatters","year":"2006","journal-title":"Trends Biochem Sci"},{"issue":"8","key":"10.1016\/j.plipres.2025.101343_bb1505","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1194\/jlr.M500114-JLR200","article-title":"The apoE isoform binding properties of the VLDL receptor reveal marked differences from LRP and the LDL receptor","volume":"46","author":"Ruiz","year":"2005","journal-title":"J Lipid Res"},{"key":"10.1016\/j.plipres.2025.101343_bb1510","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13024-019-0350-4","article-title":"APOE2: protective mechanism and therapeutic implications for Alzheimer\u2019s disease","volume":"15","author":"Li","year":"2020","journal-title":"Mol Neurodegener"},{"issue":"2","key":"10.1016\/j.plipres.2025.101343_bib1600","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1161\/01.STR.0000199065.12908.62","article-title":"Does apolipoprotein E genotype influence the risk of ischemic stroke, intracerebral hemorrhage, or subarachnoid hemorrhage? Systematic review and meta-analyses of 31 studies among 5961 cases and 17,965 controls","volume":"37","author":"Sudlow","year":"2006","journal-title":"Stroke"},{"key":"10.1016\/j.plipres.2025.101343_bb1515","doi-asserted-by":"crossref","DOI":"10.1097\/CRD.0000000000000703","article-title":"The impact of the apolipoprotein E genotype on cardiovascular disease and cognitive disorders","author":"McMaster","year":"2024","journal-title":"Cardiol Rev"},{"issue":"1","key":"10.1016\/j.plipres.2025.101343_bb1520","doi-asserted-by":"crossref","first-page":"108","DOI":"10.18632\/aging.204460","article-title":"Association between apolipoprotein E genotype and functional outcome in acute ischemic stroke","volume":"15","author":"Rong","year":"2023","journal-title":"Aging (Albany NY)"},{"issue":"Suppl_1","key":"10.1016\/j.plipres.2025.101343_bb1525","doi-asserted-by":"crossref","first-page":"ATP300","DOI":"10.1161\/str.55.suppl_1.TP300","article-title":"Abstract TP300: apolipoprotein-E deficiency and high fat diet alter immunomodulatory cellular and molecular determinants promoting atherosclerosis, a stroke risk factor","volume":"55","author":"Wesley","year":"2024","journal-title":"Stroke"},{"issue":"4","key":"10.1016\/j.plipres.2025.101343_bb1530","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.numecd.2007.01.003","article-title":"Apolipoprotein E polymorphism is associated with both carotid and coronary atherosclerosis in patients with coronary artery disease","volume":"18","author":"Gran\u00e9r","year":"2008","journal-title":"Nutr Metab Cardiovasc Dis"},{"issue":"5","key":"10.1016\/j.plipres.2025.101343_bb1535","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1038\/s41581-022-00538-3","article-title":"The evolving story of apolipoprotein L1 nephropathy: the end of the beginning","volume":"18","author":"Daneshpajouhnejad","year":"2022","journal-title":"Nat Rev Nephrol"},{"issue":"17","key":"10.1016\/j.plipres.2025.101343_bb1540","doi-asserted-by":"crossref","first-page":"1937","DOI":"10.1007\/s00018-006-6091-x","article-title":"The function of apolipoproteins L","volume":"63","author":"Vanhollebeke","year":"2006","journal-title":"Cell Mol Life Sci"},{"issue":"4","key":"10.1016\/j.plipres.2025.101343_bb1545","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1681\/ASN.2016040441","article-title":"Most ApoL1 Is secreted by the liver","volume":"28","author":"Shukha","year":"2017","journal-title":"J Am Soc Nephrol"},{"issue":"4","key":"10.1016\/j.plipres.2025.101343_bb1550","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0211559","article-title":"APOL1 renal risk variants promote cholesterol accumulation in tissues and cultured macrophages from APOL1 transgenic mice","volume":"14","author":"Ryu","year":"2019","journal-title":"PloS One"},{"issue":"12","key":"10.1016\/j.plipres.2025.101343_bb1555","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1161\/CIRCULATIONAHA.118.036589","article-title":"Association of APOL1 Risk Alleles With Cardiovascular Disease in Blacks in the Million Veteran Program","volume":"140","author":"Bick","year":"2019","journal-title":"Circulation"},{"issue":"1","key":"10.1016\/j.plipres.2025.101343_bb1560","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.ekir.2016.03.002","article-title":"Apol1 risk alleles are associated with more severe arteriosclerosis in renal resistance vessels with aging and hypertension","volume":"1","author":"Hughson","year":"2016","journal-title":"Kidney Int Rep"},{"issue":"2","key":"10.1016\/j.plipres.2025.101343_bb1565","doi-asserted-by":"crossref","first-page":"F463","DOI":"10.1152\/ajprenal.00233.2019","article-title":"APOL1 and kidney cell function","volume":"317","author":"Kumar","year":"2019","journal-title":"Am J Physiol Renal Physiol"},{"issue":"6","key":"10.1016\/j.plipres.2025.101343_bib1601","doi-asserted-by":"crossref","first-page":"106830","DOI":"10.1016\/j.isci.2023.106830","article-title":"APOL1 promotes endothelial cell activation beyond the glomerulus","volume":"26","author":"Carracedo","year":"2023","journal-title":"iScience"},{"issue":"31","key":"10.1016\/j.plipres.2025.101343_bb1570","doi-asserted-by":"crossref","first-page":"27389","DOI":"10.1074\/jbc.M110.210245","article-title":"Apolipoprotein L6, induced in atherosclerotic lesions, promotes apoptosis and blocks Beclin 1-dependent autophagy in atherosclerotic cells","volume":"286","author":"Zhaorigetu","year":"2011","journal-title":"J Biol Chem"},{"issue":"10","key":"10.1016\/j.plipres.2025.101343_bb1575","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1038\/ng.2397","article-title":"Common variants at 6p21.1 are associated with large artery atherosclerotic stroke","volume":"44","author":"Holliday","year":"2012","journal-title":"Nat Genet"},{"issue":"3","key":"10.1016\/j.plipres.2025.101343_bb1580","doi-asserted-by":"crossref","first-page":"772","DOI":"10.3324\/haematol.2022.280816","article-title":"APOLD1 loss causes endothelial dysfunction involving cell junctions, cytoskeletal architecture, and Weibel-Palade bodies, while disrupting hemostasis","volume":"108","author":"Stritt","year":"2023","journal-title":"Haematologica"},{"key":"10.1016\/j.plipres.2025.101343_bib1597","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1146\/annurev.genom.1.1.507","article-title":"Apolipoprotein E: far more than a lipid transport protein","volume":"1","author":"Mahley","year":"2000","journal-title":"Annu Rev Genomics Hum Genet"},{"issue":"11","key":"10.1016\/j.plipres.2025.101343_bb1585","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1016\/S1474-4422(17)30328-9","article-title":"Large-scale identification of clinical and genetic predictors of motor progression in patients with newly diagnosed Parkinson\u2019s disease: a longitudinal cohort study and validation","volume":"16","author":"Latourelle","year":"2017","journal-title":"Lancet Neurol"},{"issue":"1","key":"10.1016\/j.plipres.2025.101343_bb1590","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-021-23014-1","article-title":"Longitudinal analysis of blood markers reveals progressive loss of resilience and predicts human lifespan limit","volume":"12","author":"Pyrkov","year":"2021","journal-title":"Nat Commun"},{"key":"10.1016\/j.plipres.2025.101343_bb1595","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1038\/s41746-020-0260-4","article-title":"Verification, analytical validation, and clinical validation (V3): the foundation of determining fit-for-purpose for biometric monitoring technologies (BioMeTs)","volume":"3","author":"Goldsack","year":"2020","journal-title":"NPJ Digit Med"}],"container-title":["Progress in Lipid Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163782725000256?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163782725000256?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,12,6]],"date-time":"2025-12-06T21:13:12Z","timestamp":1765055592000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0163782725000256"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":326,"alternative-id":["S0163782725000256"],"URL":"https:\/\/doi.org\/10.1016\/j.plipres.2025.101343","relation":{},"ISSN":["0163-7827"],"issn-type":[{"value":"0163-7827","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Apolipoproteins in circulation: At the interface of thrombosis and stroke initiation","name":"articletitle","label":"Article Title"},{"value":"Progress in Lipid Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.plipres.2025.101343","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"101343"}}